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6ABSTRACT
Allogeneic stem cell transplantation (SCT) is an important form of treatment for
many haematological diseases. When acute complications, such as infections and
graft-versus-host disease, are treatable, more attention is paid to the long-term com-
plications of the procedure. The experience from solid organ transplantations shows
that bone loss, osteoporosis and fractures are important complications of these proce-
dures.
Consequently, the present study of patients with SCT was undertaken to answer the
following questions: I What is the magnitude and timing of bone loss? II What is the
mechanism of bone loss as examined by bone turnover markers and serum osteopro-
tegerin and RANKL measurements? III Can the bone status of SCT patients improve
spontaneously? IV How and by what mechanism does allogeneic SCT performed in
childhood affect peak bone mass in adolescence and young adulthood? V Can bone
loss be prevented by calcium, vitamin D, calcitonin, sex steroid replacement therapy
or bisphosphonates?
Altogether 187 patients with allogeneic SCT participated in the studies; 73 healthy
individuals served as controls in biochemical measurements. Bone mineral density
(BMD) was measured by dual-energy X-ray absorptiometry (DXA). Bone turnover
rate was assessed by measuring the markers of bone formation [bone-specific alkaline
phosphatase (B-ALP), type I procollagen amino- (PINP) and carboxyterminal propep-
tides (PICP) and osteocalcin (OC)] and resorption [cross-linked carboxyterminal tel-
opeptide of type I collagen (ICTP), C-terminal cross-linked telopeptide of type I colla-
gen (CTX), aminoterminal telopeptide of type I collagen (NTX) and tartrate-resistant
acid phosphatase 5 b (TRACP5b)].
During six months after SCT, BMD of the lumbar spine (LS) and the femoral neck
(FN) reduced by 5.8 % and 7.0 %, respectively. During the next six months, the LS
BMD slightly recovered but the FN BMD further decreased to 8.0%. Thirty-nine per
cent of SCT patients had either osteopenia or osteoporosis at the LS before transplan-
tation, and the number increased up to 47 % one year after SCT. At the FN, 25 % of
patients had a reduced BMD at baseline and 58 % one year after SCT.
The markers of bone formation decreased during the first three months but re-
turned to the pre-transplantation level by three months after SCT. The marker of met-
alloproteinase (MMP)-mediated bone resorption ICTP increased rapidly after SCT,
also in patients who received bisphosphonates, and remained elevated several years af-
ter SCT. Instead the markers of cathepsin-K-mediated bone resorption (CTX, NTX)
were suppressed by pamidronate therapy.  Serum osteoprotegerin, but not sRANKL
levels, was higher in patients than in controls. SRANKL levels were reduced with pa-
midronate therapy.
In the long-term adult survivors of SCT, BMD of the LS recovered almost to the
baseline level on average six years after SCT. Also BMD of the FN recovered but re-
mained reduced compared to the baseline.
On average one third of patients who have received a SCT during childhood had a re-
duced bone mass in adolescence and young adulthood. Female gender, hypogonad-
ism, prepubertal status at the time of SCT, growth retardation and low BMI were risk
factors for reduced peak bone mass.
7Calcium either alone or with calcitonin was insufficient to prevent SCT-related
bone loss. Also patients, who received a combination of calcium, vitamin D and sex
steroid replacement therapy, had a bone loss equal to those who received no bone-pro-
tecting treatment. Instead, intravenous pamidronate prevented lumbar spine bone
loss and significantly reduced, but did not totally abolish, it at the upper femur.
In conclusion, BMD of both the lumbar spine and the upper femur significantly de-
creases after SCT. At the LS bone loss spontaneously recovers. The major mechanisms
behind SCT-associated bone loss are decreased bone formation and increased bone re-
sorption; the inhibition of OPG production or excess of sRANKL do not seem to con-
tribute to bone loss. Of the options to prevent bone loss studied, pamidronate was
most efficient, but even it was in capable of totally abolishing bone loss at the hip. A
reason for the relative inefficacy of pamidronate therapy might be continued MMP-
related bone resorption, which cannot be prevented by bisphosphonates.
8ABBREVIATIONS
AA= aplastic anaemia
ALL= acute lymphoblastic leukaemia
AML= acute myeloblastic leukaemia
ANOVA= analysis of variance
BMC= bone mineral content
BMD= bone mineral density
BMT= bone marrow transplantation
Bone ALP= bone-specific alkaline
phosphatase
BSP= bone sialoprotein
BW= body weight
CLL= chronic lymphocytic leukaemia
CML= chronic myeloid leukaemia
Crea= creatinine
CTX= type I collagen carboxy-termi-
nal telopeptide
CY= cyclophosphamide
CyA= cyclosporine A
25-OH-D=25-hydroxyvitamin D
1,25-(OH)
2
-D= 1,25-dihydroxyvita-
min D
24,25-(OH)
2
-D= 24,25-dihydroxyvi-
tamin D
Dpy= deoxypyridinolene
DXA= dual energy X-ray absorptiom-
etry
EGF= epidermal growth factor
EIA= enzyme immunoassay
ELISA= enzyme linked immunoab-
sorbent assay
FGF= fibroblast growth factor
FN= femoral neck
GH= growth hormone
GHL= galactosyl-hydroxylysine
Gla= γ-carboxyglutamic acid
GVHD= graft-versus-host disease
GY= Gray
HLA= human histocompatibility leu-
kocyte antigen
ICTP= type I collagen carboxytermi-
nal telopeptide
IGF-I= insulin-like growth factor I
IL= interleukin
IRMA= immunoradiometric assay
LS= lumbar spine
MDS= myelodysplastic syndrome
MF= myelofibrosis
MP= methylprednisolone
MM= multiple myeloma
MMF= mycofenolate mofetil
MMP=matrix metalloproteinase
MTX= methotrexate
NHANES=national health and nutri-
tion examination study
NTX= type I collagen aminoterminal
telopeptide
OC= osteocalcin
OPG= osteoprotegerin
PICP=type I procollagen carboxyter-
minal propeptide
PINP= type I procollagen aminoter-
minal propeptide
PTH= parathyroid hormone
PTHrP= PTH related peptide
Pyr= pyridinoline
QCT=quantitative computed tomog-
raphy
RANK= receptor activator of NF-κB
RANKL= receptor activator of NF-κB
ligand
RIA= radio immunoassay
SCT= stem cell transplantation
SD= standard deviation
SE= standard error
SPA= single photon absorptiometry
TBI= total body irradiation
TNF- α= tumour necrosis factor- α
TRACP5b= tartrate-resistant acid
phosphatase 5b
TBMC= total body mineral content
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1 INTRODUCTION
Allogeneic stem cell transplantation (SCT) is an important treatment for many
haematological malignancies and some other diseases. In Finland allogeneic
SCTs are concentrated in Helsinki and Turku University Hospitals. At Helsinki
University Central Hospital, the Division of Haematology of the Department of
Medicine carries out about 70-90 transplantations per year and the Hospital of
Children and Adolescencents about 30 transplantations per year. When acute
complications of these procedures, especially infections and graft-versus-host
disease (GVHD), are now usually successfully managed, more attention is paid
to the long-term complications of SCT. Five years after SCT, 50 % of those who
have a non-related donor and even 80 % with sibling-donors are alive (Dun-
combe 1997).
It has been previously known that bone loss and osteoporosis are common af-
ter solid organ transplantations (Rodino and Shane 1998). These patients have
an increased risk of fractures, especially painful vertebral fractures, the incidence
of which can be even 50 % after cardiac or liver transplantation (Meyes et al
1994, Shane et al 1996).
When the present series of investigations was started there were only a few,
cross-sectional studies showing that patients with SCT were also at risk of re-
duced bone mass (Kelly et al 1990, Castañeda et al 1997). No prospective studies
were available.
Several factors in patients with SCT might affect bone metabolism. The hae-
matological disease itself or infections associated both to the disease and its
treatments enhance production of cytokines.  Interleukins 1 and 6, in particular,
are harmful to bones (Mundy 1996). High-dose chemotherapy and total body
irradiation (TBI) lead to amenorrhoea and oestrogen deficiency in women (Kel-
ly et al 1990, Boosma et al 2002). TBI can also result in the deficiency of growth
hormone (GH), which is essential for bone growth in children and for main-
taining bone mass in adults (Hovi et al 1990, Talvensaari et al 1994). Chemo-
therapy of the haematological disease can enhance bone loss (Epstein 1996). The
most dangerous threats for bone health are immunosuppressive regimens,
mainly cyclosporine A (CyA) and glucocorticoids, which are used to prevent
and treat acute or chronic graft-versus-host disease (GVHD) (Epstein 1996).
Glucocorticoids both inhibit bone formation and enhance bone resorption
(Lukert and Raiz 1990). CyA increases both bone formation and resorption, the
latter more than the former with the net effect being bone loss (Epstein 1996,
Movsowitz et al. 1988).
Osteoclast differentiation and activation are regulated at the local level by the
relative expression of a recently found receptor activator of nuclear factor-κB
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ligand (RANKL) and osteoprotegerin (OPG), which are produced by osteob-
lasts, bone marrow stromal cells and T-lymphocytes (Simmonet et al 1997).
RANKL acts on osteoclast precursors and mature osteoclasts through its recep-
tor RANK to increase osteoclast differentiation and activation. OPG instead
functions as a decoy receptor able to neutralise both the cell-bound and soluble
forms of RANKL (Lacey et al 1998).
Recent studies have shown that recipients of heart, kidney, liver and lung
transplants benefit from bisphosphonate therapy with respect to their bone sta-
tus (Reeves et al 1998, Krieg et al 2001, Grotz et al 2001, Henderson et al 2001,
Shane et al 2004) but before the start of the present investigations bisphospho-
nates had not been tested in SCT recipients and only a few studies on recipients
of other organ transplants were available.
The purpose of this study was to examine the magnitude, mechanisms, preven-
tion and spontaneous recovery of bone loss in adult SCT recipients. Some of
these aspects were also addressed in young adults who had received a SCT in
childhood.
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2 REVIEW OF LITERATURE
2.1 Bone functions and anatomy
2.1.1 Functions of bone
Bone is connective tissue, which together with cartilage builds up the skeletal
system. It serves as a mechanical support and a site of muscle attachment. Mus-
cles and the skeletal system together make locomotion possible. Furthermore,
bone protects vital solid organs and bone marrow. Moreover, bone serves as the
storehouse of the ions, especially calcium, phosphorus and magnesium (Baron
1996).
2.1.2 Bone macroscopic organisation
There are two types of bone. Trabecular or spongy bone, which makes up about
20 % of the skeleton, is found in flat bones, like the skull or the scapula, in verte-
brae and in metaphyseal areas of long bones. Cortical or compact bone is found
in the diaphyses of long bones. Trabecular bone is several times metabolically
more active than cortical bone, and its function is mostly metabolic, whereas
cortical bone takes care of support and protection (Baron 1996).
2.1.3 Bone microscopic organisation
Bone is composed of 70 %  minerals and 30 %  organic components. The main
mineral is hydroxyapatite [3Ca
3
(PO
4
)
2
(OH)
2
], comprising 95 % of the mineral
component. The rest is mostly calcium carbonate, citrate and magnesium. The
most important organic constituent is type I collagen. In addition, there are
noncollagenous proteins like osteocalcin, osteonectin and osteopontin. Two per-
cent of the organic component is composed of different bone cells. In mature
bone, the structural and functional basis is a multicellular unit or bone remod-
elling unit, that is, an osteon (Baron 1996). Total body calcium content is about
1000 g and it is mostly stored in bone as hydroxyapatite. Also 85 % of the body
phosphorus and 50 % of the body magnesium reside in bone (Breslau 1996).
2.1.4 Osteoblasts
Osteoblasts originate from mesenchymal stem cells, which proliferate and differ-
entiate into preosteoblasts and then to mature osteoblasts. They are responsible
for bone formation. They synthesise collagen and other proteins. Osteoblasts
line the layer of bone matrix, which they  produce. They produce first osteoid
tissue, which in 10 days calcificates into mature matrix. Toward the end of the
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secreting period, osteoblasts become isolated into bone lacunae, and some oste-
oblasts become osteocytes (Puzas 1996, Boyle et al 2003).
2.1.5 Osteoclasts
Osteoclasts are responsible for bone resorption. They originate from haemat-
opoietic mononuclear cells. Mononuclear osteoclast precursors circulate in the
blood. At endosteal bone surfaces, they proliferate and fuse to form multinucle-
ate cells. They secrete lysosomal and nonlysosomal enzymes and hydrogen ions.
They mobilise hydroxyapatite crystals from type I collagen and degrade colla-
gen. So calcium and inorganic phosphate are released from the degrading ma-
trix into the circulation (Mundy 1996, Boyle et al 2003).
2.1.6 Osteocytes
Osteocytes are osteoblasts, which have become encased in calcified bone. Ap-
proximately 15 % of osteoblasts become osteocytes. Metabolic activity of osteo-
cytes is low because they are encades in mature bone and their nutrition comes
only from small canaliculi (Puzas 1996).
2.2 Bone remodelling and its regulation
2.2.1 Bone remodelling
Bone growth in length is dependent upon the proliferation of cartilage cells in
the growth plate followed by maturation of these cells and endochondral ossifi-
cation. Growth in width is accomplished by the formation of bone at periosteal
surfaces and by resorption at endosteal surfaces. When the epiphyses are closed
at the age of about 15-18, bone growth in length ends. However, it is essential
for bone strength and for the regulation of mineral metabolism that bone re-
modelling continues throughout life.
Figure 1 shows the bone remodelling cycle in trabecular bone. Bone remodel-
ling constitutes the resorption of old bone and its replacement with new bone.
This remodelling takes place by teams of cells called osteons. In trabecular bone,
they are saucer-shaped  Howship’s lacunae and in cortical bone cylindrical
structures called Haversian units. The remodelling cycle comprises five phases.
First in the activation phase osteoclasts are activated and wander to a resorption
site. In the second phase they start to resorb old bone. They secrete enzymes and
hydrochloride acid, which dissolve the mineral. At low pH cysteine proteinases,
like cathepsin-K begin to digest bone matrix. When the pH rises matrix metallo-
proteinases (MMPs) complete the digestion (Evert et al 1998, Garnero et al,
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1998, Teronen et al 1999 Atley et al 2000, Garnero et al 2003). In the third phase
macrophage-like cells finish the resorption and prepare the site for bone form-
ing cells. In the synthesis phase, osteoblasts fill the cavity with new bone, which
mineralises, and a new osteon is completed. Normally bone formation and re-
sorption are closely tied to each other. In trabecular bone, the remodelling cycle
lasts about 100 days and in cortical bone about 200 days (Aurbach et al 1992b).
Remodelling is regulated by systemic hormones and local factors, which affect
bone resorbing and forming cells. Uncoupling, which means imbalance between
bone formation and resorption, leads to disorders in bone metabolism.
2.2.2 Sex steroids
Oestrogens play an important role in the regulation of bone remodelling both
in males and females. In males they are formed from testosterone by extrago-
nadal aromatase enzymes. In bone, oestrogens inhibit bone resorption, to a
great extent through osteoblastic receptors by down-regulating the expression
of bone resorbing cytokines, such as interleukins (IL)-1α, IL-1β, IL-6 and tu-
mour necrosis factor- α (TNF- α). Lack of oestrogens leads to an increased
number and activity of these cytokines. Consequently, especially in  trabecular
bone the interval between remodelling cycles shortens and at the osteon level
both bone resorption and formation are accelerated, but resorption is quicker
than formation (Kelly et al 1990, Brinhurst et al 1998, Riggs 2002).
Androgens may increase bone formation and by increasing muscle mass they
increase the mechanical load on the bones and thus strengthen them (Brinhurst
et al 1998).
2.2.3 Parathyroid hormone
Parathyroid hormone (PTH) is secreted by the parathyroid glands. Its main
function is to keep the concentration of ionised calcium in blood and extra-cel-
lular fluids constant. It activates the liberation of calcium and phosphate from
bone. It stimulates the resorption of calcium and inhibits that of phosphate in
the renal tubules. It also stimulates the renal synthesis of 1,25-dihydroxyvitamin
D [1,25-(OH)
2
-D], and consequently, the intestinal absorption of calcium (Aur-
bach et al 1992a).
When constantly elevated in serum and extra-cellular fluids PTH is a strong
stimulator of bone resorption leading to bone loss but when given intermittent-
ly in suitable doses it stimulates bone formation more than resorption thus in-
creasing bone mass (Slovik et al 1986, Black et al 2005, Cosman et al 2005).
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2.2.4 Vitamin D
Vitamins D is a fat-soluble, steroid-related family of molecules, which are both
synthesised in the body and derived from diet. 7-dehydroxycholesterol is synthe-
sised by the skin to cholecalciferol (vitamin D
3
) with exposure to ultraviolet
light. Cholecalciferol also comes from diet. Ergocalciferol (vitamin D
2
) origi-
nates from plants. Vitamin D (both D
2 
and D
3
) needs two hydroxylations to be-
come biologically active. The first hydroxylation takes place in the liver to form
25- hydroxyvitamin D (25-OH-D). 25-OH-D is further hydroxylated in the
proximal tubules of the kidneys to 1,25-(OH)
2
-D or calcitriol, which is the most
active vitamin D metabolite. A part of 25-OH-D is hydroxylated to 24,25-dihy-
droxyvitamin D [24,25-(OH)
2
-D] (Canalis 1996).
Vitamin D increases the absorption of calcium and phosphate in the gut and
increases the resorption of calcium in the renal tubules. In the short term calci-
triol inhibits osteoblast function, and increases osteoclastogenesis by up-regu-
lating the synthesis of the receptor activator of nuclear factor-κB ligand (RAN-
KL) and by down-regulating osteoprotegerin (OPG). Instead, in the long term
it stimulates osteoblasts and the synthesis of osteocalcin (Brinhurst et al 1998,
Canalis 1996).
2.2.5 Calcitonin
Calcitonin is secreted by C-cells of the thyroid gland. An increase in serum calci-
um stimulates calcitonin secretion. It decreases bone resorption by inhibiting
osteoclasts through direct action on the osteoclastic calcitonin receptors (Delfos
1996).
2.2.6 Growth hormone and insulin-like growth factor –I
Growth hormone (GH) is a pituitary peptide hormone, which is needed to
build up and maintain bone mass. GH deficiency in children leads to impaired
growth but also to reduced bone mass (Shore et al 1980, Kaufman et al 1992,
Saggese et al 1996). Also in adults GH is needed to maintain bone mass (Olney
2003). Partly GH acts by increasing the hepatic production of insulin-like
growth factor –I (IGF-I), which is a potent stimulator of bone growth. It in-
creases collagen synthesis and decreases its degradation (Canalis 1996, Olney
2003).
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2.2.7 Glucocorticoids
Glucocorticoids are adrenal hormones, which decrease bone formation by in-
hibiting the differentiation of osteoblasts. They also increase bone resorption
both directly and through secondary hyperparathyroidism by decreasing calci-
um absorption in the gut and by increasing calcium excretion into urine. They
decrease type I collagen formation and increase the expression of collagen de-
grading enzymes, like matrix metalloproteinases (MMP:s), in bone. They also
impair the synthesis of skeletal growth factors (Lukert and Raisz 1990, Canalis
2003). The latest studies support the theory that the direct effects of glucocorti-
coids on the bone are more important than the secondary ones (Shaker and
Lukert 2005). Bone loss induced by glucocorticoid treatment is dose-dependent
and is observed within a few days after starting the therapy (Sambrook et al
1994a).
2.2.8 Local regulation of bone remodelling
Figure 2 summarises the local regulation of bone remodelling. Local factors,
which are synthesised by skeletal, stromal, haematopoietic or immune cells,
have a very important role in the regulation of bone remodelling. From the
cytokine family IL-1α, IL-1β, IL-6 and TNF- α are potent stimulators of bone
degradation and inhibitors of bone formation. Interferon-γ inhibits osteoclast
function and bone resorption. Transformal growth factor- α (TGF- α) and epi-
dermal growth factor (EGF) increase bone degradation. Granulocyte-macro-
phage- (GM-CSF) and macrophage colony stimulating factors (M- CSF) en-
hance osteoclast differentation. Bone morfogenic proteins (BMPs), TGF- β,
1,25-(OH)
2
-D, MMPs and bone lining cells are proposed to have a role in cou-
pling bone remodelling. Prostaglandins have many effects on bone remodelling.
Bone cells synthesise IGF-I and IGF-II, which enhance bone collagen and matrix
synthesis. Also fibroblast growth factor (FGF) and platelet-derived growth fac-
tor (PDGF) act on bone. They stimulate collagen synthesis (Canalis 1996, Boyle
et al 2003).
2.2.9 Osteoprotegerin and RANKL
Osteoclast differentiation and activation are regulated at the local level by the
relative expression of RANKL and OPG, which are produced by osteoblasts,
bone marrow stromal cells and T-cells (Simmonet et al 1997). RANKL acts on
osteoclast precursors and mature osteoclasts through its receptor RANK to in-
crease osteoclast differentiation and activation. OPG instead acts as a decoy re-
ceptor that is able to neutralise both the cell-bound and soluble forms of RAN-
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KL (Lacey et al 1998). The expression of RANKL and OPG are regulated by
many factors, such as PTH, 1,25-(OH)
2
-D, vitamin D
3 
and oestrogens (Fohr et
al 2003).
2.3. Bone life span
2.3.1 Accumulation
The accumulation of bone mass implies increases in bone volume and mineral
content. It is a dynamic process, in which both bone resorption and formation
are needed for the development of normal bone architecture and mass. Twin
studies have shown that peak bone mass is determined mostly by genetic factors,
which explain up to 80 % of variance (Slemenda 1991).
However, the accumulation of 20 % of the individual peak bone mass is affect-
ed by environmental factors, like nutrition, exercise, smoking and medications
(Välimäki et al 1994, Lehtonen-Veromaa et al 2000). The adequate supply of cal-
cium, phosphorus, magnesium and vitamin D is essential for skeletal growth
during childhood and adolescence and to maintain bone mass in  adulthood
(Breslau 1996, Välimäki et al 2004).
Before puberty, girls and boys have an equal skeletal size and volumetric bone
mineral density (Bonjour et al 1991). During the pubertal growth spurt, skeletal
mass doubles (Riggs 2002). In males bone mass continues to increase until the
age of 15-18 , but in females the accumulation of skeletal mass dramatically
slows down between the second and fourth year after menarche, usually before
the age of 15 (Bonjour et al 1991). By the time of the epiphyseal plate closure,
the volumetric BMD has reached about 90-95% of peak mass (Kröger et al 1993,
Riggs 2002). The skeleton is then consolidated to its maximal BMD by continued
periosteal apposition and by trabecular thickening by the end of the second dec-
ade (Theintz et al 1991). Due to a longer pubertal growth spurt and the effect of
testosterone, which results in a greater bone size, males end up with 25% greater
areal peak bone mass than females (Riggs 2002).
In addition to bone mass, bone strength depends on its structural (geometry,
shape, micro architecture) and material (collagen quality, mineralisation)
properties. Any disturbance in bone accumulation can lead to lowered peak
bone mass and impaired bone quality and consequently, to an increased risk of
osteoporosis and fractures (Aurbach et al 1992b).
2.3.2 Ageing
The velocity of bone loss increases during ageing. BMD begins to decrease in
both sexes before 30-35 years of age, but before menopause in females and in
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young adulthood in males the net loss is slow due to a slow remodelling rate. Af-
ter menopause bone loss accelerates in women. Women lose about half of their
bone mass by age 80 and men 25-30 %, respectively. Bone geometry changes
only a little (in width) after growth stops (Aurbach et al 1992b, Seeman 2004).
Thereafter bone formation decreases and to lesser extent bone resorption in-
creases. Both males and females lose equal amounts of trabecular bone but in
males thinning of trabeculae dominates whereas in females loss of connectivity is
the main feature. Net cortical bone loss is less in males than in females because of
greater periosteal apposition (Seeman 2004).
2.4 Measurement of bone mineral density
2.4.1 Techniques for measurement of bone mineral density
Conventional radiography shows bone loss when 30-50 % of bone mineral con-
tent has disappeared, thus being a very insensitive way of measuring BMD.
Single photon absoptiometry (SPA) utilises 125I (27 keV) coupled with a scin-
tillation detector, which scans across the interested area, most commonly the
peripheral sites of the tubular bones. Single energy X-ray absoptiometry uses an
X-ray source in scanning appendicular sites. These techniques cannot be used to
study the vertebrae or other bones surrounded by fat and muscles. In scanning
these sites, dual photon absoptiometry (DPA) can be used. It utilises usually
153Gd, which emits photons at two energies (44 and 100 keV). This technique is
expensive and the half-life of the isotope is short. Dual energy X-ray absorpti-
ometry (DXA) uses X-rays instead of isotopes and has replaced DPA in clinical
practice (Kanis 1994b).
In quantitative computed tomography (QCT) thin slices through the body
are imaged, and the images are quantified to measure the volumetric BMD. This
technique is very sensitive and it can separate trabecular and cortical bone, but
it is expensive and the radiation exposure is high (Kanis 1994b). The latest tech-
niques are based on microCT or magnetic resonance imaging and can give an
image of the quality of the bone. Until now they have been used in studies but
they are not yet widely used clinically (Chesnut et al 2005).
2.4.2 Dual energy X-ray absorptiometry
Because of a short scanning time (about 5 minutes), low radiation exposure (< 1
µSv), low precision error (0,5-2 %) and tolerable costs, DXA is today a widely-
used method for the measurement of BMD (Kanis 1994a). In DXA an X-ray
tube produces photons with two different energy levels, high and low, and thus
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enables the evaluation of the areal densities of different tissues. The photons are
detected after exiting from bone in the region of interest and measured by a
computer, which converts them into determinations of bone mineral content
(BMC). Areal BMD (grams/cm2) is counted by dividing BMC values of the pro-
jected areas of bone analysed (Genant et al 1989). Disadvantages of the method
are that it does not take into account the three-dimensional bone size and shape,
and  does not separate trabecular and cortical bone (Kröger 1995). BMD values
are compared to databases of healthy people of different ages and both sexes to
calculate Z- and T-scores. The Z-score compares the measured value to those of
people of the same age and gender and the T-score to the peak bone mass of the
healthy individuals (20-40 years of age) of the same sex. One unit in these scores
represents one standard deviation from the mean value of the reference popula-
tion. According to WHO criteria, a T-score  <_  -1<-2,5 means osteopenia, and T-
score <_ -2,5 means osteoporosis (Kanis 1994a).
2.5 Biochemical markers of bone metabolism
There is a panel of biochemical markers, which can be used to quantify bone me-
tabolism. These assays measure in serum or in urine enzymes or matrix proteins
synthesised by bone cells or the degradation products of bone matrix. They can
be divided into those measuring bone formation and  those quantifying bone
degradation (Kanis 1994b).
2.5.1 Markers of bone formation
2.5.1.1 Alkaline phosphatase
The common form of alkaline phosphatase (ALP) is a cell-membrane-associated
enzyme, which is expressed by the liver,  bone,  kidneys and placenta. In adults
the liver and the bone are the major sources of ALP. In bone ALP is derived from
osteoblasts and their precursors, and it has a role in bone mineralisation. ALP
may increase the local concentration of inorganic phosphate, destroy local in-
hibitors of crystal growth, transport phosphate and act as a calcium-binding
protein (Kanis 1994b, Calvo et al 1996). To be used as a marker of bone forma-
tion, the bone-specific isoform (bone ALP) has to be distinguished from the liv-
er-specific-isoform. This can be done by using an immunoradiometric (IRMA)
method, an ELISA, an immunoextraction or an electrophoresis (Behr and Bar-
net 1986, Magnusson 1998).
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2.5.1.2 Osteocalcin
Human osteocalcin (OC) is a 49-residue polypeptide of γ-carboxyglutamic acid
(Gla), which is synthesised by mature osteoblasts during the mineralisation
phase of bone remodelling in a vitamin K-dependent carboxylation process. Vi-
tamin D modulates the OC-gene (Stein et al 1996). OC is found also in other cal-
cified tissues like dentin and calcified cartilage. In the bone it forms about one
per cent of the organic matrix. OC is released into the circulation during the
bone formation, and it is filtered in the kidneys (Eyre 1996). However, as OC is
incorporated into the bone extracellular matrix, some of the circulating OC
might originate from degrading bone. Thus circulating OC may rather reflect
bone turnover than bone formation alone (Riggs et al 1986). OC can be meas-
ured by an IRMA method (Garnero et al 1992).
2.5.1.3 Type I collagen propeptides
Type I collagen is synthesised by osteoblasts from type I procollagen precursor
proteins. These precursors have large extension domains at both ends. While
type I collagen is synthesised, these type I aminoterminal and carboxyterminal
propeptides, PINP and PICP respectively, are enzymatically removed and re-
leased into the circulation (Calvo 1996). While the bone is the major organ syn-
thesising type I collagen, PINP and PICP reflect bone formation (Delmas 1992,
Ebeling et al 1992, Calvo et al 1996). PINP and PICP are degraded in the liver
and elevated serum levels have been measured in patients with chronic liver dis-
ease (Guanabens et al 1996). PINP and PICP can be measured by immunoassays
(Melkko et al 1990, Melkko et al 1996).
2.5.2 Markers of bone degradation
2.5.2.1 Hydroxyproline
Collagen contains high amounts of hydroxyproline (HOP), and during its
breakdown HOP is released into the blood. HOP has been traditionally used as
a marker of bone degradation. It is not specific to bone collagen and this togeth-
er with contributions from diet and the degradation of free amino acids in the
liver makes it a very unspecific way to measure bone resorption (Eyre 1996).
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2.5.2.2 Pyridinoline cross-links
Collagen molecules are held together by hydrogen bonds and pyridinium cross-
links. When collagen degrades, these cross-links [pyridinoline (Pyr), deoxypy-
ridinoline (Dpy)] are released into the circulation, and then excreted into urine.
Because the bone is the major reservoir of the type I collagen, and turns over
faster than most major connective tissues, pyridinolines in adult urine are most-
ly derived from bone and thus reflect bone resorption. Urinary Pyr and Dpy can
be measured by immunoassays. There is a wide intra-individual variation, and
results should be related to urine creatinine (Eyre 1996).
2.5.2.3 Hydroxylysine
Hydroxylysine is formed from lysine during the posttranslational phase of colla-
gen synthesis and is incorporated into bone matrix as a component of collagen
molecules. It occurs in two glycosylated forms, glycosyl-galactosyl-hydroxyly-
sine and galactosyl-hydroxylysine (GHL). GLH is more bone-specific, and it is
released into the circulation during collagen degradation. Both can be measured
by an immunoassay in the urine (Fohr et al 2003).
2.5.2.4 Tartrate-resistant acid phosphatase
Tartrate-resistant acid phosphatase is an enzyme, the 5b-isoform (TRACP 5b) of
which is expressed in high amounts in osteoclasts. During bone degradation
TRACP5b is released into the circulation. It has been shown to be elevated in pa-
tients with metabolic bone diseases. It seems to be a quite sensitive and specific
marker of bone resorption. It reflects both cathepsin-K- and MMP-mediated
bone degradation. During bisphosphonate therapy serumTRACP5b decreases.
(Halleen et al 2001, Janckila et al 2001, Tähtelä et al 2005, Välimäki and Tähtelä
2005) TRACP5b can be measured in the serum by an immunoassay based on a
highly characterised specific monoclonal antibody (Halleen et al 2000).
2.5.2.5 Cross-linked telopeptides of type I collagen
When type I collagen is degraded it is split into several fragments. Cathepsin-K
and MMPs take part in this process. Two fragments have been characterised in
the carboxyterminal end of the type I collagen. The first is a cross-linked carbox-
yterminal telopeptide of type I collagen (ICTP) and the second a C-terminal
cross-linked telopeptide of type I collagen (CTX).  ICTP is a larger molecule
than CTX (Garnero 2003). There is a type I collagen aminoterminal telopeptide
(INTP or NTX) in the aminoterminal end. It is thought that cathepsin-K releas-
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es mostly CTX and NTX and MMPs ICTP (Garnero et al 1998, Atley et al 2000,
Sassi et al 2000, Garnero et al 2003). ICTP can be measured in serum and CTX
and NTX in urine or serum by immunoassays (Hanson et al 1992, Risteli et al
1993, Bonde et al 1994). These markers have been shown to be elevated in pa-
tients with metabolic bone diseases and metastatic bone diseases (Tähtelä and
Thölix 1996, Fohr et al 2003, Garnero 2003). During antiresorptive treatment
serum or urine concentrations of CTX and NTX, but not serum ICTP, decrease
(Christhau et al 2000).
2.5.2.6 Bone sialoprotein
Bone sialoprotein (BSP) is a glycoprotein produced by osteoblasts. It is glyco-
sylated and incorporated into bone matrix during bone formation. It accounts
for 10-15 % of non-collagenous organic matrix. During bone degradation it is
released and can be measured in serum by an immunoassay (Fohr et al 2003).
2.6 Stem cell transplantation
2.6.1 Autologous stem cell transplantation
Autologous stem cell transplantation (SCT) is an important treatment method
of haematological malignancies and some other diseases. In autologous SCT,
haematological stem cells are mobilised and harvested either from peripheral
blood or sometimes from the bone marrow. Thereafter, the patient is condi-
tioned with high-dose chemotherapy. Then the stem cells are infused back into
the patient. No anti-GVHD medication is needed because the infused cells are
the patients’ own (Duncombe 1997).
2.6.2 Allogeneic stem cell transplantation
Allogeneic SCT is used to treat haematological malignancies and some other
haematological diseases. The bone marrow of the patient is destroyed before
transplantation. A classical treatment is total body irradiation (TBI) with 12
Gy (lungs 10 Gy) divided into fractions of 2 Gy and given over five days. TBI is
combined with chemotherapy, which in most cases consists of a high dose of cy-
clophosphamide. There are protocols using other regimens with or without
TBI. Thereafter stem cells, which have been harvested either from an HLA-iden-
tical sibling or from a matched unrelated donor, are infused into the patient
(Duncombe 1997, Bensinger and Spielberger 2004, Shank and Hoppe 2004).
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2.6.3 Graft-versus-host disease
Graft-versus-host disease (GVHD) is a situation in which transplanted immune
cells attack  the recipient’s cells causing clinically variable, and at worst life-
threatening, symptoms. All patients receiving allogeneic SCT get immunosup-
pressive treatment against GVHD. The basic immunosuppressive regimen has
traditionally been cyclosporine A (CyA). In most cases a short course of meth-
otrexate (MTX) is used at the beginning of the procedure.  Glucocorticoids es-
pecially methylprednisolone (MP) also belong to the protocols. In recent years
new drugs, which are widely used to prevent rejection in solid organ transplan-
tations, like mycofenylate mofetil (MMF) and tacrolimus, have also been stud-
ied in SCT. Antilymphocyte globulin can be used instead of MP especially in pa-
tients with an unrelated donor. In spite of prophylaxis, acute or chronic GVHD
can complicate the course of SCT. Acute GVHD is treated with a high-dose of
MP and chronic GVHD with MP, CyA, MMF or thalidomide (Thomas et al
1975, Duncombe 1997, Sullivan 2004).
2.7 Transplantation associated bone disease
2.7.1 Differences between solid organ and stem cell transplantations
Patients receiving SCT are immobilised and receive immunosuppressive treat-
ment like other transplantation patients (Stern et al 1996). There are, however,
some differences between solid organ and stem cell transplantations. Patients re-
ceiving SCT are often younger and their illness has lasted for a shorter time than
that of patients with solid organ transplantation. If SCT recipients do well, im-
munosuppressive treatment can be stopped about one year after SCT, which is
not the case in patients with solid organ transplants. Another major difference
in the treatment is that SCT patients receive high-dose chemotherapy and in
many cases total body irradiation (TBI) before transplantation (Bensinger and
Spielberger 2004, Shank and Hoppe 2004).
2.7.1.1 Effect of chemotherapy
Glucocorticoids are a part of many haematological treatment protocols. They
inhibit bone formation and enhance bone resorption when measured by bio-
chemical markers of bone metabolism (Carlson et al 1994, Arikoski et al 1999b).
Their effects on bone are discussed in more detail later (Chapter 2.7.7.4). BMD
has shown to be reduced after leukaemia treatment (Arikoski et al 1999a) and
after high-dose chemotherapy for non-Hodgkin lymphoma and breast cancer
(Banfi et al 2001). Methotrexate (MTX) is a folate antagonist, which has been
related to severe osteopenia especially in children, but also in adults (Epstein
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1996). MTX is thought to increase bone resorption and urinary and faecal ex-
cretion of calcium (Kaste et al 1999).  Ifosfamide-associated bone loss has also
been described (Kaste et al 1999). One mechanism behind chemotherapy-associ-
ated bone loss might be its toxicity to bone marrow osteoprogenitors, which are
precursors of bone-forming cells (Bhatia et al 2001). High-dose cyclophospha-
mide leads to gonadal impairment and to amenorrhoea, infertility and lack of
oestrogen in females and gonadal impairment and at least in high doses infertili-
ty in males (Kelly et al 1990, Sanders et al 1996, Boomsma et al 2002).
2.7.1.2 Total body irradiation
TBI impairs growth hormone excretion (Hovi et al 1990, Talvensaari et al 1994).
Lack of GH leads to impairment of skeletal growth in children, but also reduces
BMD in adults (Holmes et al 1994). Skeletal irradiation may directly interfere
with skeletal growth and cause direct bone loss (Neuhauser et al 1952). The sur-
vivors of childhood ALL, who had received cranial irradiation, had lowered
BMD (Gilsanz et al 1990). Instead in those survivors of childhood ALL, who had
not received TBI, BMD of the lumbar spine (LS) and total body did not differ
from healthy controls (Brennan et al 2005). TBI may also damage the gonads
and thereby cause hypogonadism (Shubert et al 1990, Kauppila et al 1998).
2.7.1.3 Effect of haematological disease
It is well known that plasmacytomas of bone cause significant morbidity to pa-
tients with multiple myeloma (Body et al 1998).  Patients with acute lymphob-
lastic leukaemia (ALL) also have reduced bone turnover at the time of diagnosis
either due to cytokines produced by ALL-cells or secondarily to depressed pro-
collagen synthesis caused by occupation of the synthetic capacity by leukaemia
cell mass (Sorva et al 1997). Infections associated with malignant diseases en-
hance the production of cytokines (Mundy 1996). It has been shown that after
allogeneic SCT the serum concentrations of osteoclast-activating cytokines IL-6
and TNF-α increase (Lee et al 2002b, Lee et al 2004).
2.7.2 Bone mineral density after solid organ transplantation
It has been known since the 1990s that the recipients of heart, kidney, lung and
liver transplants are at increased risk of osteoporosis. The decrease in BMD is
fastest during the first 6 months after transplantation, but it continues at least
one year after the transplantation (Katz and Epstein1992, Rodino and Shane
1998). Older patients had significantly higher rates of bone loss (Olivari et al
1988, Muchmore et al 1992).
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In cardiac transplant recipients, the reduction in BMD was from 6 to 10 % at
the lumbar spine during the first 6 months (Sambrook et al 1994, Välimäki et al
1999) and from 6 % to 14 % at the femoral neck (FN) during the first year (Van
Cleemput et al 1995, Välimäki et al 1999). The lumbar BMD stabilises after 6
months, the hip BMD after the first year, but the radial BMD continues to fall
during the second and third year (Cohen and Shane 2003, Maalouf and Shane
2005).
Children, who had received a cardiac transplant at least one year before BMD
measurement, had lower Z-scores at the lumbar spine (LS), femoral neck (FN)
and total body than age-matched healthy controls (Daniels et al 2003).
In kidney transplant recipients, BMD decreases by 4 to 9 % at the LS and 5 to 8
% at the FN during 6-18 postransplant months. At the same time 17-49 % pa-
tients have osteoporosis at the LS, 11-56 % at the FN and 22-52 % at the radius
(Julian et al 1991, Grotz et al 2001, Cohen and Shane 2003, Maalouf and Shane
2005). There is one study of kidney transplant recipients, which showed only 2.4
% decrease in lumbar spine BMD and no changes at the femoral neck within six
months post transplantation (Miklus et al 2003). A steroid-sparing immunosup-
pressive protocol was used in this study.
One year after kidney transplantation child patients had lowered z-scores in
the total body (Daniels et al 2003).
The spinal BMD of the liver transplant recipients decreased by 2-24 % during
the first year (Meys et al 1994, Cohen and Shane 2003, Compston 2003). A spon-
taneous recovery of BMD during the second and third year after liver transplan-
tation has been documented (Cohen and Shane 2003, Maalouf and Shane 2005).
After lung transplantation the lumbar and femoral BMD decreased by 2-5 %
during the first year and 73 % of the patients had osteoporosis (Cohen and
Shane 2003, Maalouf and Shane 2005).
2.7.3 Bone mineral density after allogeneic stem cell transplantation
Table 1 summarises the major findings of studies of bone metabolism after SCT.
Before the present study there were several small studies in patients with SCT: A
cross-sectional study (n=23) showed lowered bone mass after SCT (Kelly 1990).
In another study 33 % of the patients had osteopenia and 18 % osteoporosis
about three year after receiving SCT (total n=27) (Castañeda et al 1997). The
only small (n=9) longitudinal study showed a reduction in BMD 9 months after
the beginning of the prophylaxis of GVHD (Stern et al 1996).
In a more recent longitudinal study 29 recipients of allogenic SCT lost 11.7 %
of their femoral neck BMD, 3.9 % of their lumbar spine BMD and 3.5 % of their
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total body mineral content (TBBMC) during approximately 30 months after
SCT (Ebeling et al 1999). In another study (n=81) bone loss was 7.2 % at the
lumbar spine BMD, 11.9 % at the femoral neck BMD and 3.8 % at the TBBMC
after one year of SCT (Schulte et al 2000). The third study (n=67) showed that
49 % of SCT patients had osteopenia even before the transplantation. During
the first six and twelve post transplant months trabecular bone BMD decreased
by 13 % and 17 % and cortical BMD by 9.8 % and 9 %, respectively, when meas-
ured by QCT (Messenkeil et al 2001). In the fourth study (n=67) the lumbar
spine BMD decreased by 3.3 % and the femoral neck BMD by 8.9 % during the
first year after SCT (Lee et al 2002a).
A 2-year longitudinal study of 35 patients showed a slight increase in the spinal
BMD from one to two years after SCT, and a further loss in the femoral neck
BMD at the same time (Schulte et al 2000). A cross-sectional study performed
approximately three years (range 1-10 years) after SCT (n=41) showed that
BMD in transplantation patients was significantly lower than in controls and 37
% of them had osteopenia and 15 % osteoporosis at the LS (Tauchmanova et al
2002). With phalangeal osteosonogrammetry 60 % of patients had osteopenia
and 7 % osteoporosis. The longer after transplantation the better bone status
patients had especially in the lumbar spine (Tauchmanova et al 2002). Other
studies (n=44-102) have demonstrated that the femoral neck BMD is lowered
several years after SCT (Buchs et al 2001, Gandhi et al 2003). The latest study, in
which 280 SCT recipients were followed for at least 4 years, demonstrated that
the nadir in the reduction of BMD was achieved at 6 months in the lumbar spine
and at 24 months in the femoral neck (Schulte and Beelen 2004). Another cross-
sectional study (n=22) showed that 28 % of SCT recipients had osteopenia at
the LS and 48 % at the FN approximately 5 years after SCT (Kerscah-Schindl et
al 2004).
Studies of paediatric populations (combined n=95) have shown a slight de-
crease in Z-scores at the LS, FN and in the whole body at least 1 year after SCT
(Nysom et al 2000, Daniels et al 2003). The latest study of paediatric SCT pa-
tients (n=48) showed that 26 % of them had osteopenia (defined as a Z-score be-
tween –2 and –1) and 21 % osteoporosis (Z-score lower than –2) approximately
5.5 years after SCT (Kaste et al 2004). In one study, which included both paedi-
atric and adult patients (n=28), total body BMD in Z-scores was significantly
lower in paediatric patients (Z-score –0,5) than in the adult population (Z-
score 0,0) when measured about two years after SCT (Bhatia et al 1998).
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2.7.4 Fractures and avascular necrosis after solid organ and stem cell transplanta-
tion
2.7.4.1 Fractures
The recipients of solid organ transplants have an increased risk of fractures.
Eight per cent of patients with renal transplantation had fractures during the
first two post transplant years (Ramsay-Goldman et al 1999). The fractures af-
fected mostly appendicular sites like the hip, long bones and feet (prevalence 10-
50 %) than axial sites (prevalence 3-10 %). Females and patients with diabetes
had a higher risk of fractures (Ramsay-Goldman et al 1999, Cohen and Shane
2003).
Cardiac transplant recipients have a 22-35 % prevalence of the vertebral frac-
tures during the first post-transplant year (Shane et al 1993), the incidence of
new vertebral fractures during the first year being 28-36 % (Shane et al 1996,
Välimäki et al 1999, Leidig-Bruckner et al 2001).
After liver transplantation the fracture rate ranges from 24 to 65 % during the
first year after the transplantation and the majority of fractures affect the ribs
and vertebrae (Leidig-Bruckner et al 2001, Cohen and Shane 2003). There has
been a tendency to a decreased incidence of fractures in recent years, which is
proposed to be due to steroid-sparing immunosuppressive protocols (Comp-
ston 2003).
Eighteen to 37 % of lung transplant recipients get fractures (Shane et al 1999,
Cohen and Shane 2003).
In stem cell –transplanted patients the incidence of vertebral or non-vertebral
fractures during the first year after SCT has varied from 1 to 16 % (Stern et al
1996, Ebeling et al 1999, Schulte et al 2000).
2.4.7.2 Avascular necrosis
Avascular necrosis of bone is characterised by areas of necrosis of bone and bone
marrow of the long bones, especially femur, tibia and humerus (Enright et al
1990). The incidence of the avascular necrosis after allogeneic SCT is 8.1-10.4 %.
It is described as affecting most commonly hip, knee, ankle and shoulder joints
(Enright et al 1990, Socié et al 1994, Tauchmanova et al 2003). The incidence of
avascular necrosis in patients with autologous transplantation was 0-1.9 % (En-
right et al 1990, Tauchmanova et al 2003). In all of these studies the incidence of
avascular necrosis was correlated to acute or chronic GVHD needing glucocor-
ticosteroids, increasing age and in one study to the male gender (Tauchmanova
et al 2003). Patients with avascular necrosis have decreased fibrinolytic potential
(Van Veldhuizen et al 1993). In paediatric patients 44 % had had osteonecrosis
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approximately 5.5 years after SCT (Kaste et al 2004).
2.7.5 Markers of bone turnover after solid organ transplantation
In a histomorphometric analysis of bone biopsies from liver transplant recipi-
ents, bone turnover, both formation and resorption, was increased when com-
pared to the low turnover state before the transplantation (Vedi et al 1999). Af-
ter kidney transplantation, histomorphometric studies have shown increased
bone resorption and osteoblastic dysfunction with a defect in the mineralisation
(Julian et al 1991, Cohen and Shane 2003). After cardiac transplantation, the
markers of bone formation (serum PINP, PICP, OC) decrease and the markers of
resorption (serum ICTP, urinary HOP) increase within the first weeks and
months. Bone turnover remains high at least 6-12 months after the procedure
(Rich et al 1992, Shane et al 1993, Sambrook et al 1994, Thiebaud et al 1996,
Välimäki et al 1999). In lung transplant recipients, bone turnover markers are
consistent with both increased resorption and formation (Cohen and Shane
2003).
2.7.6 Markers of bone turnover after allogeneic stem cell transplantation
Table 1 shows major changes in bone markers after SCT. Bone ALP and PINP de-
creased 3 weeks to 3 months after SCT. Thereafter, these markers returned to the
baseline by 6 months and tended to be even higher at 12 months after than be-
fore SCT (Carlson et al 1994, Ebeling et al 1999). Similar results have been re-
ported in studies with serum OC as the marker of bone formation (Gandhi et al
2000, Kang et al 2000, Buchs et al 2001). Several years after the transplantation,
serum OC was within the reference limits (Castañeda et al 1997).
In one small study (n=27) the markers of bone resorption, ICTP and HOP
were elevated several years after SCT (Castañeda et al 1997). Serum ICTP has
been shown to be elevated even before transplantation and the level further in-
creased during the first months after SCT and then decreased but remained
higher than before SCT (Kang et al 2000, Lee et al 2002a). The acceleration of
bone resorption after SCT has been documented also by using assays of urinary
HOP (Stern et al 1996), CTX (Banfi et al 2001), NTX (Schulte et el 2000) and py-
ridinium cross-links (Ebeling et al 1999).
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2.7.7 Mechanisms of transplantation associated bone loss
2.7.7.1 Role of underlying disease
There are many reasons why BMD might be worse in chronically ill patients.
The impaired hydroxylation of 1,25-(OH)
2
-D, secondary hyperparathyroidism
and consequent osteitis fibrosa, adynamic bone disease and osteomalacia are
important metabolic complications of kidney dysfunction and lead to bone
morbidity (Gonzáles and Martin 2003). Cholestatic liver disease may impair the
formation of 25-OH-D (Katz and Epstein 1992). Heart failure patients use loop
diuretics, which lead to a negative calcium balance, and many have smoked
(Katz and Epstein 1992). Patients with chronic lung diseases might be smokers
and many of them have used glucocorticoids (Cohen and Shane 2003).
2.7.7.2 Immobilisation
Severe chronic disease leads to immobilisation, which leads to rapid bone loss
especially in hospitalised patients both in adults (Le Blanc et al 1990) and in
children (Tillman et al 2002).   Resistant exercise training has been shown to re-
store BMD in heart transplantation patients (Braith et al 1996).
2.7.7.3 Immunosuppressive treatment
All transplanted allograft organs are at a great risk of undergoing a rapid and
progressive immune-mediated injury or rejection, which threatens the progno-
sis of the transplanted organ and in the worst cases also that of the patient re-
ceiving the allograft. Thus, all patients receiving a transplanted organ need im-
munosuppressive regimens. The traditional strategy consists of CyA, azathio-
prine and glucocorticoids, most often methylprednisolone (MP). During the
past decade  new agents have also been developed and in many cases azathio-
prine is replaced by mycophenolate mofetil (MMF), and also tacrolimus instead
of CYA and sirolimus instead of azathioprine or MMF are in clinical use (Den-
ton et al 1999).  CyA and MP, in particular, may have an important role in
transplantation-associated bone disease (Epstein 1996, Rodino and Shane 1998).
2.7.7.4. Glucocorticoids
Although glucocorticoids inhibit T-cell proliferation and the expression of the
genes of such cytokines as IL-1, IL-6, interferon and TNF, which are all implicat-
ed in bone resorption, they produce rapid and profound bone loss (Epstein
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1996). Approximately 10 mg of prednisolone and prednisone or their equiva-
lents daily is enough to cause bone loss during the first six months after the start
of treatment. Even a lower daily dose of 7.5 mg prednisolone may lead to bone
loss when used for long periods (Shane and Epstein 1994, Shaker and Lukert
2005). Besides osteoporosis glucocorticoids expose their users to avascular
necrosis and even fractures, when BMD is still normal (Canalis et al 2004, Shak-
er and Lukert 2005).
Glucocorticoids have many systemic effects, which indirectly affect the bone.
They reduce intestinal calcium absorption and increase urinary calcium excre-
tion, which both secondarily increase PTH excretion. Furthermore, glucocorti-
coids decrease the secretion of growth hormone and gonadal and adrenal an-
drogens and oestrogens (Lukert and Raisz 1990). They also enhance osteoclastic
activity possibly through secondary hyperparathyroidism (Rodino and Shane
1998, Canalis 2003).
In the bone they decrease osteoblast recruitment and differentiation, increase
osteoblast apoptosis and inhibit synthesis of type I collagen, and then decrease
bone formation (Schäcke et al 2002, Shaker and Lukert 2005). Two mechanisms
behind increased resorption are the up-regulation of RANKL and the inhibition
of OPG, which have been demonstrated in in vitro studies (Hofbauer et al 1999a,
Hofbauer et al 1999b) and in patients who have received prednisolone for acute
respiratory obstruction (Bornefalk et al 1998).
2.7.7.5 Cyclosporine A
CyA is a small fungal cyclic peptide, which upon administration forms a com-
plex with cytoplasmic receptor protein. This primary complex binds calcineurin
A and B, calcium and calmoduline and forms secondary complexes, which pre-
vent the action of new nuclear regulatory protein and T-cell genes (Epstein
1996). In animal models rapid bone loss has been demonstrated after adminis-
tration of 7.5 to 15 mg /kg of CyA (Movsowitz et al 1989). CyA enhances both
bone resorption and formation but the rate of resorption is higher. Consequent-
ly the markers of bone formation and resorption increase after CyA administra-
tion (Guañabens et al 1992, Thiébaud et al 1996). CyA also inhibits the synthesis
of 1,25-(OH)
2
-D in the kidneys (Rodino and Shane 1998) and the production of
OPG and stimulates the production of RANKL (Hofbauer et al 1999a, Hofbauer
et al 1999b). In cardiac transplant recipients, the cumulative dose of CyA is in-
versely correlated with age-matched BMDs (Rich et al 1992).
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2.7.7.6 Other immunosuppressive agents
Azathioprine is a derivative of mercaptopurin. It may suppress osteoblastic ac-
tivity and activate osteoclasts but it does not seem to affect bone mass (Bryer et
al 1995).
Tacrolimus is a fungal macrolide, which acts in a similar fashion as CyA (Ep-
stein 1996). In animal models it seems to have the same kind of effect on bone as
CyA (Rodino and Shane 1998). After cardiac transplantation, patients receiving
tacrolimus had a remarkable bone loss (Stemple et al 2002). In rats MMF had no
effect on bone accumulation but human data on MMF action in the bone is lack-
ing (Rodino and Shane 1998). In animal models rapamycin or sirolimus in-
crease bone remodelling and inhibit longitudinal bone growth (Epstein 1996).
2.7.7.7. Osteoprotegerin and RANKL
In animal models OPG-deficient mice develop rapid and severe osteoporosis
(Bucay et al 1998, Krane 2002, Fohr et al 2003) and at the same time their vessels
calcify (Bucay et al 1998). In a cross-sectional study serum OPG levels were low-
er in cardiac transplant patients than in healthy controls. In a prospective study
of the same authors OPG level was normal before cardiac transplantation but
decreased after transplantation and the decrease was correlated to bone loss af-
ter transplantation (Fahrleitner et al 2003).  After renal transplantation the se-
rum OPG level has also been shown to decrease (Sato et al 2001). In another
study of this patient group, serum OPG and RANKL did not differ from healthy
controls 42 months after transplantation (Malyszko et al 2003). In patients with
liver transplantation, serum OPG did not differ from healthy controls when it
was measured about 20 months after transplantation (Fahrleitner et al 2002).
In a very recent study serum OPG increased progressively during the first
three weeks after SCT and declined thereafter. In this study sRANKL was not de-
termined (Baek et al 2004). In another cross-sectional study, SCT recipients had
an elevated serum OPG level approximately 5 years after transplantation (Ker-
schan-Schindl et al 2004).
2.7.8 Prevention of transplantation-associated bone loss
2.7.8.1 Calcium and vitamin D
It is recommended that all transplant recipients should receive calcium (1000 to
1500 mg /day) and vitamin D (400 to 800 IU/ day) supplements although with-
out other measures they are insufficient to prevent bone loss (Van Cleemput et al
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1996, Välimäki et al 1999, Pisani et al 2002, Cohen et al 2004). High doses of
more potent vitamin D metabolites have in some studies increased BMD of
heart-transplanted patients (Van Cleemput et al 1996, Garsia-Delgado et al
1997). In one study 0.25 µg alfacalcidol per day decreased, but did not totally
prevent, bone loss at the LS and the FN at one year after kidney transplantation
(El-Agroudy et al 2003). In the latest study of cardiac transplant recipients, cal-
citriol prevented lumbar spine and reduced femoral neck bone loss as effectively
as alendronate (Shane et al 2004).
2.7.8.2 Sex steroid replacement therapy
Severe disease can cause amenorrhoea in premenopausal women. Oestrogen re-
placement therapy with progestin has been shown to inhibit bone loss and to
prevent fractures in oestrogen-deficient women (Cauley et al 2003). In one study
of postmenopausal women with liver transplants, transdermal oestrogen started
approximately 4.1 years after the transplantation and increased both femoral
neck and lumbar spine BMD during  the following two years (Isoniemi et al
2001).
There is only one study of oestrogen replacement therapy in SCT patients.
When started about thirteen months after SCT, it increased BMD, which was at
the osteopenic level in nine out of thirteen patients before treatment (Castelo-
Branco et al 1996).
Chronically ill men have often hypogonadism and immunosuppressive regi-
mens can impair the production of testosterone even more (Rodino and Shane
1998). Serum testosterone decreases after cardiac transplantation but in most
cases returns to the baseline level during the first year after transplantation
(Shane et al 1997, Välimäki et al 1999). Testosterone replacement therapy in-
creases BMD in hypogonadal men (Snyder et al 2000). Similar evidence on
transplantation patients is lacking but treatment with testosterone of truly hy-
pogonadal men is recommended (Rodino and Shane 1998).
2.7.8.3 Calcitonin
Intra-nasally administrated salmon calcitonin has prevented corticosteroid-as-
sociated bone loss (Rodino and Shane 1998) and it can be used in postmenopau-
sal osteoporosis (Thamsborg et al 1991). In one non-randomised study of cardi-
ac transplantation patients, calcitonin slightly reduced bone loss (Muchmore et
al 1992) but in randomised studies with cardiac transplant recipients it had no
effect on BMD either alone (Garcia-Delgado et al 1997) or with calcium
(Välimäki et al 1999).
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2.7.8.4 Bisphosphonates
Bisphosphonates are drugs that inhibit osteoclastic function and thus prevent
bone resorption. They can be administrated either orally (alendronate, clodro-
nate, etidronate, risedronate) or intravenously (ibandronate, pamidronate,
zoledronic acid). They all have a long half-life. Their efficacy has been well docu-
mented in the prevention of bone loss and fractures in postmenopausal women
(Cummings et al 1998, Pols et al 1999), and in long-term users of glucocorticoids
(Adachi et al 2000, Reid et al 2000). In per oral use gastrointestinal side effects
are comon, because these preparations are acidic. Infused preparations may
cause flu-like symptoms. They can worsen kidney insufficiency and cause ady-
namic bone disease in patients with decreased kidney function (Canalis et al
2004).
A relatively weak bisphospohonate etidronate used cyclically (400 mg for two
weeks every three months) appeared to be unable to prevent bone loss in pa-
tients after cardiac (Garcia-Delgado et al 1996, Van Cleemput et al 1996) or liver
transplantation (Riemens et al 1996).
In comparison to historical controls a single intravenous dose of 60 mg pa-
midronate followed by cyclic etidronate decreased bone loss and reduced frac-
ture rate after cardiac transplantation (Shane et al 1998). In another study of
cardiac transplant patients with osteoporosis before transplantation, intrave-
nous pamidronate (60 mg at 3 months intervals for 3 years) resulted in a signifi-
cant increase in BMD both at the LS and FN whereas patients with normal BMD
treated with calcium and vitamin D, lost bone (Krieg et al 2001). Thirty mg of
intravenous pamidronate given at three months’ intervals improved both femo-
ral neck and lumbar spine BMD in osteopenic cardiac-transplant recipients
when started about 1.7 years after transplantation (Dodidou et al 2003). In the
latest study oral alendronate prevented lumbar spine and reduced femoral neck
bone loss when started immediately after transplantation (Shane et al 2004).
After kidney transplantation both LS and FN BMD increased significantly in
patients who received oral alendronate 10 mg daily started at least 6 months af-
ter transplantation. At the same time patients on calcium and vitamin D supple-
ments only had stable BMD (Giannini et al 2001). In another study patients
who received 1 mg of intravenous ibandronate before and 3, 6 and 9 months af-
ter kidney transplantation had significantly less bone loss at the LS and even a
slight increase in the FN BMD compared to those who got only calcium and vi-
tamin D (Grotz et al 2001). In one study two infusions of 4 mg of zoledronic
acid with an interval of three months prevented bone loss at the FN and even
improved lumbar spine BMD six months after kidney transplantation (Haas et
al 2003).
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In osteoporotic liver transplant recipients one-year treatment with cyclic etid-
ronate improved BMD when started approximately 17 months after the trans-
plantation (Valero et al 1995). Of patients with reduced bone mass before liver
transplantation, those who received 60 mg of intravenous pamidronate every
three months before and for 9 months after transplantation had no new verte-
bral fractures whereas 38 % of those not receiving pamidronate experienced ver-
tebral compression fractures (Reeves et al 1998).
Lung transplantation patientswho received two cycles of etidronate after the
transplantation had less bone loss during the first six months compared to un-
treated controls and the protective effect of etidronate remained for up to one
year after the transplantation (Henderson et al 2001).
Except for one uncontrolled study with pamidronate (Buchs et al 2001), the
efficacy of bisphosphonates in the immediate prevention of bone loss after SCT
has not been evaluated to date. When started for treatment of osteopenia or
rapid bone loss 17 to 24 months after SCT risedronate and zoledronic acid in-
creased the LS BMD by 4.4-9.8 % and the FN BMD by 5.9-6.4 % at one year
(Taucmanová et al 2003, Tauchmanová et al 2005).
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3 AIMS OF THE STUDY
The aim of the present study was  to evaluate bone loss following allogeneic SCT
and to answer the following questions.
I What is the magnitude and timing of bone loss?
II What are the mechanisms of bone loss as examined by bone turnover mark-
ers and serum osteoprotegerin and RANKL measurements?
III Can the bone status of SCT patients improve spontaneously?
IV How and by what mechanism does allogeneic SCT performed in childhood
affect peak bone mass in adolescence and young adulthood?
V Can bone loss be prevented by calcium, vitamin D, calcitonin, sex steroid re-
placement therapy or bisphosphonates?
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4 PATIENTS AND METHODS
4.1 Patients
The characteristics of the patients are shown in Table 1. All the patients received
an allogeneic SCT at the Helsinki University Central Hospital. Those, whose dis-
ease had begun in childhood, were treated at the Hospital for Children and Ad-
olescents, and adult patients at the Division of Haematology, Department of
Medicine. Patients who had renal insufficiency, diseases affecting bone metabo-
lism or multiple myeloma as an indication of SCT were excluded.
4.1.1 Prospective study of bone loss after stem cell transplantation and the effect
of calcium with or without calcitonin (Study I)
Sixty-one patients who underwent allogeineic SCT were included in the first
study. Twenty-five patients were lost for the follow-up within six months after
SCT (9 due to death, 4 due to a relapse, 2 due to a critical and complicated situ-
ation and 10 were unwilling to continue due to nausea caused by the study med-
ication). A further 8 patients died before one year after SCT. Because of the
dropouts, 8 participants of an earlier pilot study were included in the BMD
analyses. Thus 44 patients (21 men and 23 women) completed 6 months follow-
up and 36 (16 men and 20 women) 12 months follow up. The mean age was 40
(SD 9) years. The diagnoses were AML (N=17), ALL (n=6), CML (n=15), MDS
(n= 5) and Burkitt’s lymphoma (n=1). Due to menopausal symptoms, oestro-
gen replacement therapy was started for 20 women during the study, with a me-
dian of 171 (range 40-319) days after SCT.
4.1.2 Follow-up study of adult stem cell transplant recipients (study II)
For the second study the 29 participants of the first study, who were still alive,
were invited to a control visit with a median of 75 (range 54-96) months after
SCT. Twenty-seven of them (13 men and 14 women) accepted the invitation.
Their median age at the time of the study was 44 years and their diseases were
ALL (n=2), AML (n=12), Burkitt’s lymphoma (n=1), CML (n=10) and MDS
(n=2). All the women were still using oestrogen replacement thepary and none
of the men used regular testosterone replacement. One man had received testo-
sterone for 7 months due to impotence. Twelve patients had used treatment for
GVHD longer than one year after SCT. At the time of the study one patient was
still using CyA and another patient had used it longer than one year after SCT.
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Twelve patients had used glucocorticoids longer than one year. Two of the female
patients had started bisphosphonate therapy because of prolonged glucocorti-
coid use.
4.1.3 Stem cell transplantation in  childhood (Study III)
For the third study 25 young adults and adolescents who had received an alloge-
neic SCT in childhood, were invited to the examinations with a median of 7.1
(range 1.5-20.5) years after SCT. Sixteen (6 males and 10 females) were willing
to take part in the study. At the time of the examination, the age of the patients
varied from 16 to 34 (median 21) years. The underlying diagnoses were AML
(n=5), ALL (n=5), CML (n=2), myelodysplasia (n=1) and aplastic anaemia
(n=3). Eight patients had received SCT before puberty.
4.1.3 Stem cell transplantation in  childhood (Study III)
One hundred and fifteen adult recipients of an allogeneic SCT were screened and
99 of them were randomised for study IV. Seventy-two patients were followed at
least 6 months after SCT. Twenty-three patients died, 1 had a relapse of the hae-
matological disease, 1 got another malignancy and 2 were unwilling to continue.
Sixty-seven patients completed the study protocol, also 5 were lost before 12
months’ follow-up; 4 due to death and 1 because bisphosphonate therapy had
been started outside the trial. Thus 72 patients were followed at least for 6
months and 66  for 12 months. Their median age was 43 (10) years and the diag-
noses were ALL (n=10), AML (n=20), lymphoma (n=4), CML (n=27), CLL
(n=4), MF (n=4) and MDS (n=3).
4.1.5 Serum osteoprotegerin and RANKL after SCT (Study V)
Thirty (14 men and 16 women) participants of  study IV, whose serum samples
had been stored at -80° Celsius comprised one study group in  study V. Fourteen
patients had received pamidronate (eight women, six men) and 16 patients
(eight women, eight men) were treated with calcium, vitamin D, and sex steroid
replacement therapy only. The mean age was 40 (10) years and indications for
SCT included ALL (n=4), AML (n=9), lymphoma (n=1), CML (n=10), CLL
(n=3), MF (n=2) and MDS (n=1). Another patient group consisted of 28 SCT
recipients (14 women and 14 men), whose mean age was 41 (12) years and diag-
noses ALL (n=5), AML (n=14), amyloidosis (n=1), CML (n=6), CLL (n=1) and
hybrid leukaemia (n=1). All were using calcium and vitamin D and all women
except 2 women oestrogen.
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4.1.6 Healthy controls
In study II an equal number of sex-matched healthy controls from health care
staff were recruited for biochemical analyses. They were somewhat younger than
the patients [35 years (SD 12) versus 44 (9) years (p=0,005)]. Also for  study III
22 (12 females and 10 males) age- and sex-matched controls were recruited for
determination of the markers of bone metabolism.
In  study V 21 healthy volunteers (11 women and 10 men) served as controls
for biochemical analyses.
4.2 Stem cell transplantation procedure
In study I the patients received stem cells from an HLA-identical sibling except
three who had a matched, unrelated donor. Those participating in  study II all
had sibling donors. Of those who had received SCT in  childhood 11 had a relat-
ed and 5 an unrelated donor from the Finnish national registry or international
registries. In study IV 41 patients received a transplant from a sibling and 31 pa-
tients from an unrelated donor. In the first group of study V 17 patients had a
related and 13 an unrelated donor, and in the second group 15 and 13 patients,
respectively.
Before SCT adult patients had been conditioned with CY 60 mg/kg body weight
(BW) intravenously on 2 consecutive days, and with total body irradiation 12
Gy (lungs 10 Gy) in six fractions of 2 Gy over 5 days. Instead of irradiation two
patients in  studies I and II received busulfan 4 mg/kg BW intravenously daily
for 4 days before SCT.
All but one patient, who had received SCT in childhood, had been conditioned
with total body irradiation (TBI). The irradiation dose was either of 10 (n=8),
12 (n=6) or 14 (n=1) Gys. In addition cytarabin or CY 60 mg/kg BW was ad-
ministered on 2 consecutive days or CY 50 mg/kg BW on 4 consecutive days if
TBI was not given.
4.3 Prevention and treatment of GVHD
CyA, MTX and MP were most commonly used to prevent and treat GVHD.
CyA was initiated on  day —4 before transplantation and given with a dose of 3
mg/kg BW per day as a continuous intravenous infusion for two weeks. The dose
was modified to keep the whole blood cyclosporine A concentration at the level
of 400 µg /l. Thereafter, CyA was taken orally and for the next 10 weeks the
whole blood cyclosporine A concentration was kept between 100 and 200 µg/l if
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the donor was a sibling, and between 200 and 300 µg/l if the donor was unrelat-
ed. Thereafter, the concentration was kept near 100 µg /l and 100-200 µg /l, re-
spectively. CyA was administered for nine months and tapered off in approxi-
mately six weeks. Nine patients in the study IV were switched from CyA on my-
cofenolate mofetil due to side effects caused by CyA. Six of those were also par-
ticipants in  study V. In another group of study V five patients were using MMF
instead of CYA.
MTX was given intravenously 15 mg/m2 one day before SCT and 10 mg/m2 on
days +3, +6 and +11 after SCT.
MP was started orally 14 days after SCT at a dose of 0.5 mg/kg BW for a week,
then the dose was doubled for 2 weeks, and thereafter halved every third week
and stopped by day +110 after SCT. Four participants of study I did not receive
routine MP. Those with an unrelated donor in study IV (n=31) did not receive
routine MP but 6-12 mg/kg BW of antilymphocyte globulin (Thymoglob-
uline®, Sangstat, Lyon, France). Thirteen of those also participated in study V.
However, all except seven in  study IV and three in  study V received MP for
acute or chronic GVHD.
Acute GVHD was treated with MP starting with a dose of 10 mg/kg BW. The
daily dose of MP was halved every third day until the dose was approximately 1
mg/kg BW and it was thereafter tapered off individually. Chronic GVHD was
treated with a low dose of MP alone or in combination with CyA, thalidomide
or MMF.
4.4 Study design
4.4.1 Prospective study of bone loss after stem cell transplantation and the effect
of calcium with or without calcitonin
In  study I, patients were randomised to three groups. The first group (n=22) re-
ceived no additional treatment, the second group (=12) got oral calcium
(Mega-Calcium®, Sandoz, Basel, Switzerland); calcium lactate gluconate 5,23 g,
calcium carbonate 0,8 g) 1 g twice daily and the third group (n=10) oral calci-
um 1 g twice daily and intranasal calcitonin (Miacalcic®, Sandoz) 400 IU per
day during the first month and then 200 IU per day during the next eleven
months. All female patients started oestrogen replacement therapy with a medi-
an of 170 (range 40-365) days after SCT. All study groups were similar in age [40
years (SD 10) in the reference group, 40 (8) years in the calcium-group and 41
(12) in the calcium and calcitonin group], but differed with respect of female
preponderance in the calcium group (10 women and 12 men in the reference
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group, 9 women and 3 men in calcium group, 4 women and 6 men in the calci-
um and calcitonin group).
BMD was measured before and 6 and 12 months after SCT. Spine x-ray was
taken before and 12 months after SCT. Venous blood samples were taken for de-
termination of serum bone ALP, PICP, PINP, ICTP, ionised calcium, phospho-
rus, creatinine, magnesium and testosterone in men before and 3 and 6 weeks
and 3, 6 and 12 months after SCT. In eight people of the reference group (partic-
ipants of the previous pilot study) only BMD was measured before and 12
months after SCT.
4.4.2 Follow-up study of adult stem cell transplant recipients
In  study II BMD was measured and a spine x-ray was taken at the follow-up vis-
it. After an overnight fast, blood was sampled for determination of serum ion-
ised calcium, creatinine, PINP, ICTP, osteocalcin, 25-OH-D and testosterone in
men and oestradiol in women. The second 2-hour morning void was collected
for determination of urine NTX. Life habits of patients were ascertained using a
questionnaire, which was filled in by the patients.
4.4.3 Stem cell transplantation in  childhood
In study III blood was sampled for the determination of serum osteocalcin, cal-
cium, albumin, ICTP, PINP, 25-OH-D, TRACP5b, PTH, testosterone in men and
oestradiol in women. The second 2-hour morning void was collected for deter-
mination of urine NTX. Bone mineral density was measured by DXA.
4.4.4 Prevention of bone loss with calcium vitamin D, and sex steroid replace-
ment therapy with or without pamidronate
Patients were randomized by age and sex to two treatment groups. In one group
the patients (19 women and 18 men) received calcium carbonate 1000 mg and
vitamin D 800 IU daily (Ideos®, Meda, Solna, Sweden). Two weeks after SCT fe-
male patients started percutaneous estrogen replacement therapy using patches,
which release 50 mg of estradiol (Estraderm Matrix®®, Novartis, Basel, Switzer-
land) per 24 hours, and oral hydroxyprogesterone acetate 10 mg (Provera®,
Pharmacia, Bohrs, Belgium) daily during the first ten days of every month. At
the same time male patients started testosterone replacement therapy using
patches, which release 2.5 or 5 mg of testosterone per 24 hours (Atmos®, Astra-
Zeneca, Gothenburg, Sweden). The dose of testosterone was adjusted on the ba-
sis of serum testosterone level at the start of medication. In another group the
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patients (17 women and 18 men) received the same treatments mentioned above
plus six intravenous infusions of 60 mg of pamidronate (Aredia®, Novartis, Ba-
sel, Switzerland); first just before and then 1, 2, 3, 6 and 9 months after SCT.
BMD of the lumbar spine (lumbar vertebrae L1-L4) and of the three femoral
sites (femoral neck, trochanter, and total hip) was measured before and 6 and 12
months after SCT.
Serum was sampled for the determination of creatinine, ionised calcium, PINP,
ICTP, CTX, TRACP5b and estradiol in females and testosterone in males. The
second void urine samples were collected for the determination of NTX. Serum
and urine samples were collected in the fasting state in the morning by 10 a.m.
before and 1, 3, 6 and 12 months after SCT.
4.4.5 Serum osteoprotegerin and RANKL after SCT
In the first part of the study patients were randomized into two groups. One
group (eight women, eight men) received calcium, vitamin and sex steroid re-
placement as mentioned above. In another group patients (eight women, six
men) received the same treatments mentioned above plus intravenous pamidro-
nate infusions as in study IV.
Venous blood was sampled for determination of serum OPG and sRANKL be-
fore, 1, 3, 6 and 12 months after SCT and BMD before, and 6 and 12 months af-
ter SCT in the first part of the study. In the second part of the study V OPG and
sRANKL were measured with a median of 122 (range 88-163) days after SCT. In
this part BMD was not measured.
4.5 Bone mineral density measurements
In  studies I, II and IV BMD of the LS (lumbar vertebrae L1-L4) and the femoral
sites (FN, trochanter and total hip in study IV and those with Ward’s triangle in
studies I and II) was measured by dual energy X-ray absorptiometry (DXA) us-
ing Hologic QDR-1000 densitometer (Hologic, Waltham, MA, USA). In study
III the measurements were done using Lunar 10068 equipment (GE Lunar, Mad-
ison, WI, USA) and total body BMD was measured. The precision of the meth-
od (coefficient of variation) was 0.9 % at the lumbar spine and 1.2 % at the fem-
oral neck.
BMD was expressed as g/ cm2 and in study III also as standardised Z-scores,
which compare individual results with those of healthy people of the same age
and gender. BMD values were compared to the manufacturers’ Finnish databas-
es and in study III the American NHANEJ-database for the total body BMD.
45
For subjects aged less than 20 years the manufacturer’s gender-specific pediatric
reference data was used to produce lumbar spine and total body Z-scores; refer-
ence data was unavailable for the upper femur. In the adults T-scores, which
compare individual bone density measurements to those of the young (20-40
years), normal population of the same gender, were also analysed. According to
the criteria defined by WHO, T scores equal to or more than 2.5 SD below the
mean of the young normal population of the same gender, represent osteoporo-
sis, whereas T scores equal to or less than –1.0 but more than – 2.5 represent os-
teopenia (Kanis 1994).
4.6 Biochemical measurements
Intact PICP, PINP and ICTP were determined by RIA kits from Orion Diagnosti-
ca (Oulunsalo, Finland). The intra- and inter-assay CVs for these assays ranged
from 2 to 9%. The ALP isoenzymes were determined using a kit from Boehringer
Mannhein (Mannheim, Germany), in which bone-specific isoenzyme is precipi-
tated by lectin, and bone ALP activity is calculated from total and residual ALP
activity. The intra- and inter-assay CVs were 4 and 5 %, respectively. Serum os-
teocalcin was measured by an IRMA recognising intact osteocalcin and N-Mid-
fragment of the peptide (CIS Bio International, Gif-Sur-Yvette, France) with in-
tra- and inter-assay CVs of 1.5 to 4 %. Urinary NTX was measured by an auto-
mated CIA (Vitros Eci, Ortho Clinical Diagnostics, Amersham, UK) with a sen-
sitivity of 5 nmol/l, and the intra- and inter-assay CVs ranging from 2 to 10 %;
the measured values were proportioned to urinary creatinine excretion. Serum
25-OH-D concentration was measured by a RIA after acetonitrile extraction
(DiaSorin, Stillwater, MN, USA). The sensitivity of the method was 5 nmol/l, in-
tra-assay imprecision 5.9 - 8.9 %, and interassay imprecision 6.0 - 9.0 %. Serum
testosterone was assayed by an automated luminoimmunoassay (Chiron Diag-
nostics, Medfield, USA) with intra- and inter-assay CVs ranging from 4% to
7%. Serum oestradiol was measured by a RIA (Orion Diagnostica) with a sensi-
tivity of 0.02 nmol/l, and intra- and inter-assay CVs ranging from 3 to 12 %. For
determination of serum ionised calcium blood samples were centrifuged imme-
diately after being drawn, and the serum analysed with an ion selective analyser
(Microlyte, Kone Inc, Finland) within a few hours of blood collection (intra-as-
say CV 1.6%). Serum concentration of TRACP5b was assessed by an immuno-
extraction method with boneTRAPTM reagents from Suomen Bioanalytiikka
Oy (Turku, Finland). The analytical sensitivity of this assay was 0.1 U/l, and in-
tra- and inter-assay CVs of TRACP5b were 6 % or less at relevant concentra-
tion. Serum CTX was assayed by an ELISA method (Serum CrossLaps ELISA,
Nordic Bioscience Diagnostics, Herlev, Denmark). Intra- and inter-assay CVs of
the method ranged from 7% to 10%. OPG and sRANKL were determined using
EIA kits from Biomedica (Vienna, Austria) with the intra- and inter-assay coef-
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ficient of variation being 9.8% and 7.8% for OPG and 11.0% and 7.0% for
sRANKL, respectively. Serum phosphorus, magnesium and creatinine and urine
creatinine were determined by routine methods.
4.7 Life habits
Patients answered a questionnaire in which they were asked about their smoking
habits, alcohol consumption, calcium intake, medications an dmedical and frac-
ture history.
4.8 Statistics
In all the studies, data with normal distributions are expressed as means with
SDs, otherwise as medians with ranges or interquartile ranges. The significance
level used in overall tests, as well as in linear contrasts, was 0.05.
Analyses were performed as two-sided and using SAS System and SAS/MIXED
procedure in  study I, NCSS 2000 software (NCSS Statistical Software, Kaysville,
UT, USA) in studies  II, IV and V and SPSS software (SPSS Inc, Chicago, IL,
USA) in studies III, IV and V.
In comparisons between and within the study groups, normally distributed
variables were studied using repeated measures ANOVA or two group t-tests. If
the assumptions for repeated measures ANOVA (even after log transformation)
were not fulfilled, Geisser-Greenhouse adjusted P values were used. Two-sample
t-test or one-way ANOVA (percent changes) were used as appropriate. The data
not distributed normally after the log-transformation were tested with Mann-
Whitney U test or Kruskal-Wallis one-way ANOVA on ranks. BMD changes
were also analysed with ANOVA using percent changes from baseline to 6- and
12-month time-points. In the analyses of bone marker data log-transformed
percent changes from baseline to 1-, 3-, 6- and 12-month time-points were used.
Spearman and Pearson correlations were used when appropriate.
In  study III to evaluate the effect of height (as SDs from the normal popula-
tion), weight and BMI on BMD, two-way analysis of variance for Z -scores was
performed by putting each demographic variable one by one together with the
group (= normal or reduced BMD) and interaction of the variable and the
group into the model. Pearson correlation coefficients between demographic
variables and Z- scores were calculated for the whole study population and also
separately for the groups, if the above-mentioned interaction existed.
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4.9 Ethics
The Ethical Committee of the Department of Medicine, Helsinki University Cen-
tral Hospital approved study I. The Ethical Committee of the Department of
Medicine, Helsinki University Central Hospital approved studies II, IV and V.
Study III was approved by the Ethical Committee of the Diseases of Children
and Adolescents and Psychiatry, Helsinki University Central Hospital. A written
consent was obtained from all the patients.
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5 RESULTS
5.1 Magnitude and timing of bone loss
5.1.1 Bone mineral density
In study I no significant difference in bone loss between the treatment groups
(no treatment either calcium with or without calcitonin) was observed. Thus,
the groups were combined. Figure 3 shows the changes in the BMD in the com-
bined group. Bone loss at the LS, expressed as per cents from baseline, was 5.8 %
at 6 months and 3.6 % at 12 months after SCT (p<0.001). At the FN the respec-
tive decreases in BMD were 7,0 % and 8.0 (p<0.001). The trochanter BMD de-
creased by 8.2 % at 6 months and 8.3 % at12 months after SCT (p<0.001).
The majority of bone loss occurred during the first six months after SCT. At
the lumbar spine BMD even slightly recovered from 6 to 12 months after SCT
(p<0.01).
5.1.2 Osteopenia and osteoporosis
The number of patients fulfilling the WHO criteria for osteopenia and oste-
oporosis in  study I is shown in Tables 3 and 4. Thirty-nine per cent of the pa-
tients had either osteopenia or osteoporosis at the LS before SCT, 50% 6 months
and 47 % 12 months after SCT. The respective percentages at the FN were 25 %,
45 %, and 58 %. Tables 2 and 3 also show that in study IV the patients not re-
ceiving pamidronate had osteopenia and osteoporosis in quite similar percent-
ages as those in study I.
5.1.3 Fractures
Sixteen per cent out of 25 assessable patients in  study I had vertebral fractures.
Two experienced a single vertebral compression fracture, and two had multiple
fractures one year after SCT. Two of these patients belonged to the reference
group and two to the calcium supplement groups.
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5.2 Mechanisms of bone loss after stem cell transplantation
5.2.1 Markers of bone formation
Figure 4 shows changes in the markers of bone formation (bone ALP, PINP and
PICP) in study I. Because there were no significant differences in biochemical
markers between the treatment groups in study I, the groups were combined.
The markers of bone formation (bone ALP, PINP, PICP) all decreased 3 weeks to
3 months after SCT. Maximum reductions were 20 % in bone ALP at 3 weeks
(p=0.027), 40 % in PICP at 6 weeks (p<0.0001) and 63 % in PINP at 6 weeks
(p<0.0001). Thereafter all these markers returned to the baseline by 6 months
and tended to be even above the baseline at 12 months after SCT.
Approximately six years after SCT the markers of bone formation (PINP and
OC) were similar in patients and controls (study II). Serum PINP had reduced
by 30% from the level at 12 months after SCT (p=0.024).
In  study III the young patients after SCT performed during childhood did not
differ from the healthy controls with respect to the markers of bone formation
(serum osteocalcin and PINP), and the marker levels were similar for those with
normal vs. reduced BMD.
5.2.2 Markers of bone resorption
Figure 4 shows changes in the marker of bone resorption (ICTP) in  study I. Se-
rum ICTP was above the reference range even before SCT and it increased after
the procedure reaching the maximum (77 % above the baseline) at 6 weeks
(p<0.0001). Thereafter it decreased but was still above the baseline at 12 months
after SCT p>0.05).
In study II approximately 6 years after SCT, serum ICTP was still significantly
higher in patients than controls [3.93 (1.99)  µmol/l vs. 2.78 (0.69)  µmol/l,
p=0.0001] but it had significantly decreased from the level at 12 months after
SCT [6.85 (3.31)  µmol/l, p=0.018]. On the other hand, urine NTX was signifi-
cantly lower in SCT patients than in the controls [31.1 (20.2) nmol/mmol vs.
52.5 (22.0) nmol/mmol, p=0.0002].
In  study III SCT patients did not differ from the healthy controls in respect to
the markers of bone resorption (urine NTX, serum ICTP, serum TRACP 5b).
Furthermore, the marker levels were similar for those with normal and reduced
BMD.
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5.2.3 Testosterone and oestradiol
In the male patients serum testosterone decreased being at the lowest level (a 57
% reduction from the baseline) at 6 weeks after SCT (p=0.0003) (study I).
Thereafter, it returned near the pre-transplantation level by 6 months after SCT.
In  study II mean serum testosterone level had decreased from 17.4 nmol/l at 12
months to 11.7 nmol/l at the follow-up (approximately 6 years after SCT) visit
(p=0.005). Four out of the 13 men had serum testosterone level below the lower
limit of the reference range (9.0 nmol/l) and 11 men had values lower than be-
fore SCT.
In  study II all women were using oestrogen replacement therapy and had a
mean serum oestradiol level of 0.23 nmol/l, which falls within the target range
(0.1-0.3 nmol/l) in oestrogen-treated women.
5.2.4 Osteoprotegerin
Figure 5 shows changes in serum OPG in the treatment groups of the first part of
the study IV. Before SCT they were similar in patients combined [3.66 (1.76)
pmol/l] [mean (SD)] and in controls [2.89 (1.44) pmol/l] (p = 0.11). Over time
the study groups did not differ from each other (p = 0.38). During the first 6
post transplant months, the mean serum OPG increased by 26 % in the pamidr-
onate group (p = 0.028) and by 27 % (p = 0.002) in the other group. With the
study groups combined, serum OPG levels were higher in patients than controls
post transplant (p = 0.009 at 1 month, p = 0.003 at 3 months, p = 0.002 at 6
months, and p = 0.09 at 12 months). In the second part of the study serum OPG
levels for patients with a median of 122 days after SCT [6.57(1.53) pmol/l] were
clearly higher than for controls (p < 0.001).
5.2.5 sRANKL
Figure 5 shows median changes in serum sRANKL after SCT. At the baseline of
the first part of study V serum sRANKL levels were similar in patients combined
[0.33(0.15) pmol/l] and in controls [0.26(0.13) pmol/l] (p=0.12). Over time the
study groups differed from each other (p=0.050). In the pamidronate group the
mean sRANKL level decreased by 42 % at 3 months (p=0.0007) and by 38 % at 6
months (p=0.0061). In the other group it did not change significantly. In the
second part of  study V serum sRANKL concentrations were similar for patients
[0.20 (0.07) pmol/l] and controls [0.26(0.13) pmol/l] (p=0.13). Serum OPG
and sRANKL concentrations correlated inversely.
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5.2.6 Serum 25-OH-D
In study II patients examined several years after SCT had lower serum 25-OH-D
concentrations than healthy controls (27.4 [7.4] nmol/l vs. 40.6 [10.6] nmol/l,
p= 0.0002). Twenty-four out of 27 patients had a 25-OH-D level below the target
of 37.5 nmol/l; the respective numbers for the controls were 11 out of 28.
In study III the median serum level of 25-OH-D of the SCT patients with re-
duced BMD was not different from the healthy controls (p=0.43). Hypovitami-
nosis D [25-OH-D < 37.5 nmol/L] (22) was diagnosed in 6 out of 16 SCT pa-
tients (38%), but also in 8 out of 23 healthy controls (35 %).
5.3 Recovery of bone after stem cell transplantation in adults
5.3.1 Bone mineral density
Study II showed that BMD increased at all measurement sites from one year af-
ter SCT to the follow-up visit at approximately 6 years after SCT. The recovery
was statistically significant at the LS, where BMD increased by 2.4 % (p= 0.002).
The changes at the femoral sites were +4.1 % at the FN (p=0.087), +4.0 % at the
trochanter (p=0.095) and +1.4% in the total hip (p=0.23).
To find out the effect of the treatment for GVHD, the participants were divid-
ed into those who had the treatment up to one year after SCT, and to those who
needed it longer. The amount of MP used, but not that of CyA, was significantly
higher in the long-term users’ group. There was no significant difference in the
recovery of BMD between long-term versus short-term users of GVHD treat-
ment. Instead, total bone loss at the femoral sites from the pre-transplantation
level to the follow-up measurement was significantly higher in long-term versus
short-term users; -10. 5 % vs. –1.9 % at the FN (p=0.04), -13.6 % vs. –2.1 % at
the Ward’s triangle (p=0.04) and –10.1 % vs. –2.6 % at the total hip (p=0.03).
5.3.2 Osteopenia and osteoporosis and fractures
At the time of the follow-up visit 26 % of the patients had abnormally low BMD
at the LS and 41 % at the FN, the respective percentages at 12 months had been
50 % and 48 % (Tables 3 and 4).
No patients had experienced new vertebral fractures between 12 months after
SCT and the follow-up visit approximately 75 months after SCT. One man and
one woman had had a distal radial fracture; both patients had used GVHD-
treatment longer than one year after SCT.
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5.4.1. Bone mineral density
BMD data of study III are presented in Table 5. Six patients (38%) had a Z-score
less or equal to -1 at least one measurement site; they comprised the group of
patients with reduced areal bone mineral density. Z-score < -1 was detected in
the lumbar spine, the femoral neck, the total hip, and the total body in 3/16
(19%), 2/16 (12%), 1/16 (6%) and 4/16 (25%) patients, respectively.
5.4.2. Risk factors of reduced BMD
All young adult patients with reduced BMD were females (p=0.02) and they
were younger (p=0.08) at the time of the SCT than the patients with normal
BMD. The SCT patients with normal BMD did not differ from the patients with
reduced BMD in respect to a cumulative dose or the duration of use of glucocor-
ticoids, a cumulative dose of CyA, or alcohol or calcium consumption. All  6 pa-
tients with reduced BMD exercised regularly at least 1-2 times/week compared
to 4/10 of the patients with normal bone mineral density (p=0.07). All patients
were non-smokers.
Five of the 6 patients with reduced BMD had been diagnosed with a growth
delay > –1 SD after SCT as opposed to 3/10 of the patients with normal BMD
(p=0.03). Four of the six patients with reduced BMD had had growth hormone
insufficiency compared to 3/10 patients with normal BMD (p=0.10). The major-
ity of patients with reduced BMD had been prepubertal at the time of SCT (5/6
vs. 3/10, p=0.03). Five of the six patients with reduced BMD had needed sex hor-
mone substitution to induce pubertal development in contrast to 2 of the 10 pa-
tients with normal BMD (p=0.02).
5.4.3. Effect of weight and height
Since growth delay was a risk factor for reduced BMD, the effect of weight and
height (and BMI) was studied in a more detailed way. The effect of weight and
BMI on BMD was not dependent on the group (normal or reduced BMD) and
therefore, Pearson’s correlation coefficients were calculated for the whole study
population. Except for the femoral neck, the r-values between BMD and weight
or BMI varied from 0.63 to 0.69 (p = 0.003-0.02) for weight and from 0.66 to
0.76 (p = 0.0007-0.02) for BMI at the measurement sites. Instead, the effect of
height in SDs was significantly dependent on the group in the lumbar spine (p =
0.002 for the interaction between height and group) and the total body (p =
0.007) and therefore, the correlations between height and BMD were calculated
separately for the groups with normal and reduced BMD. In patients with nor-
5.4 Effect of stem cell transplantation performed in childhood on peak
bone mass
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mal BMD an expected positive correlation between BMD and height was found
for the lumbar spine (p = 0.05) and the total body (p = 0.04). However, in pa-
tients with reduced BMD the correlations were uniformly negative and signifi-
cant for the lumbar spine (p=0.008) and of borderline significance for the total
body (p = 0.09).
5.5 Prevention of stem cell transplantation- associated bone loss
5.5.1 Calcium and vitamin D
Study I showed that calcium neither alone nor with calcitonin could prevent
bone loss after the SCT. In the calcium group the BMD of the LS decreased by
3.9 % in 6 months (p<0.0001) and by 1.2 % (p<0.0001) in 12 months after SCT
and at the FN by 6.3 % in 6(p<0.0001) and 6.1 % in 12 months (p<0.0001).
In study IV calcium substitution with vitamin D and sex steroid replacement
therapy was not enough to prevent bone loss after SCT. The BMD of the LS de-
creased by 3.2 % (p= 0.005) at 6 months and by 2.9 % (p=0.031) at 12 months.
At the FN the reductions were 4.9 % (p<0.001) and 6.2 % (p<0.001), at the tro-
chanter 8.9 % (p<0.001) and 9.8 % (p<0.001) and in the total hip 7.6 %
(p<0.001) and 7.8 % (p<0.001), respectively (Figure 6).
5.5.2 Calcitonin
In study I patients with calcitonin and calcium lost 6.0 % of their lumbar spine
BMD in 6 months (p<0.0001) and 3.9 % in 12 months (p<0.0001). The respec-
tive changes at the femoral neck were 6.3 % (p<0.0001) and 8.5 % (p<0.0001).
The changes did not differ from those in the control group, not receiving any os-
teoporosis prevention.
5.5.3 Oestrogen and testosterone
Twenty out of 23 female patients in study I started oestrogen replacement with a
median of 171 (range 40-319) days after SCT and they were still using it by the
time of study II. However, it could not prevent the reduction in bone mass com-
pared to the males of study II, who had lowered testosterone levels but were not
using any substitution. In study IV all patients received sex steroid replacement
therapy but it together with calcium and vitamin D did not prevent bone loss.
(Figure 6) In the group that received only calcium, vitamin D and sex steroid re-
placement therapy the reductions in BMD were even higher (see 5.5.1) than in
the combined study groups of study I (receiving calcium with or without calci-
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tonin or no prevention of osteoporosis) [in the trochanter (8.4 % and 8.5 % at
6 and 12 months, respectively) (p=0.07) and in the total hip (6.2 % and 6.4 %,
respectively) (p=0.007)].
5.5.4 Bisphosphonates
5.5.4.1 Effect on BMD
In study IV the study groups (calcium, vitamin D and sex steroid replacement
therapy with or without pamidronate) differed significantly over time from
each other at the LS (p=0.0084), the trochanter (p=0.0040), and the total hip
(p=0.0015); at the FN the difference was of borderline significance (p=0.074)
(Figure 6). In the pamidronate group lumbar spine BMD remained stable, but
decreased in the other group by 3.2 % (p= 0.005) at 6 months and by 2.9 %
(p=0.031) at 12 months. In the femoral neck BMD of the pamidronate group
the decrease was 2.5 % (p=0.001) and 4.2 % (p<0.001) at 6 and 12 months, and
in the other group 4.9 % (p<0.001) and 6.2 % (p<0.001), respectively. The pa-
tients on pamidronate lost 3.8 % of their trochanter BMD in 6 months
(p<0.001) and 4.9 % in 12 months (p=0.001). In the other group, the respective
losses were 8.9 % (p<0,001) and 9.8 % (p<0.001). In the total hip bone loss in
the pamidronate group was 4.8 % at 6 months (p<0.001) and 5.5 % at 12
months (p<0.001) and in the other group 7.6 % (p<0.001) and 7.8 %
(p<0.001), respectively.
5.5.4.2 Effects on bone markers
Changes in the markers of bone metabolism in study IV are shown in Figure 7.
Over time the study groups differed from each other with respect to changes in
urinary NTX (p=0.035) and S-PINP (p=0.03); the differences in serum CTX
(p=0.10) and TRACP5b (p=0.077) were of borderline significance. In the pa-
midronate group, S-PINP decreased 79 % (p=0.025) during the first three
months, and remained lowered by the end of the follow-up (p=0.002). Serum
ICTP increased by 61 % (p<0.001) during the first post-transplant month. It
was still elevated at 6 months (+48 %, p<0.001). Urinary NTX decreased by 68
% during the first three months (p=0.014). Serum CTX dropped 49 %
(p=0.054) below the baseline at 3 months but was back at the baseline at 6
months. Serum TRACP5b increased non-significantly by 40 % (p=0.16) during
the first month. By the end of the follow-up it decreased to 70 % of the pre-SCT
level in the (p=0.073). In the other group, serum ICTP doubled during the first
month (p=0.001) and was significantly elevated at 6 months (+77 %, p =0.027)
and non-significantly so at 12 months. Serum TRACP5b increased by 51 % with-
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in the first post-transplant  month (p=0.022). By the end of the study it de-
creased to the pre-SCT level. Other bone markers did not change significantly
(Figure 7).
5.5.4.3 Osteopenia and osteoporosis and fractures
In study IV 31 % of the patients receiving pamidronate had at least osteopenia
at the LS before SCT, 26 % after six months and 24 % after twelve months. In the
other group, the number of patients with reduced BMD were 41 %, 46 % and 34
%, respectively. At the FN 34 % of the patients in the pamidronate group had at
least osteopenia before SCT, 37 % six months and 40 % 12 months after SCT. In
the other group the respective percentages were 43 %, 56 % and 48 %.
In study IV eight patients experienced a new, radiologically demonstrated ver-
tebral fracture; three (8.6 %) in the pamidronate group and five (13.5 %) in the
control group.
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6 DISCUSSION
6.1 Patients and methods
6.1.1Patients
In Finland allogeneic stem cell transplantations of children are concentrated at
Helsinki University Central Hospital and for adults they are carried out at Hel-
sinki and Turku University Hospitals. All university hospitals perform autolo-
gous stem cell transplantations. All the patients of the present study had their
SCT in Helsinki. During the first year after the transplantation patients are
closely followed-up by the Division of Haematology, Department of Medicine,
Helsinki University Central Hospital. Before SCT most of the patients had been
treated in other university and central hospitals in Finland. Therefore, only
transplantation-associated treatments are described in this study.  The amounts
of glucocorticoids, in particular, used before the SCT remained unknown in
most cases. However, Finnish haematologists follow the same recommendations
in treatment of basic haematological diseases and thereby, it is apparent that the
previous treatments did not differ significantly between the patients (Finnish
Leukaemia Group).
Patients with multiple myeloma were excluded from the study but otherwise
the patients represented a typical SCT population. Also the mortality of our
SCT patients, 29 % during the first year, was comparable with that in previous
studies (Duncombe 1997). Transplantation procedures and prevention and
treatment of GVHD followed international guidelines (Bensinger and Spiel-
berger 2004).
In study I 21 of the original 69 patients stopped the study before six months af-
ter transplantation. Because of this high discontinuation rate we decided to in-
clude eight participants of an earlier pilot study in this study population. In
them the SCT had been performed in a similar way as in the other patients. They
did not receive any special prevention for bone loss but had BMD measurements
before and 6 and 12 months after SCT.
Currently study IV is the largest published, prospective, randomised study on
the prevention of bone loss in SCT patients, and the only one in which preven-
tive therapies were started immediately after SCT.
6.1.2 Measurement of bone mineral density
DXA was chosen as the BMD measurement method because it is easily and rap-
idly performed, it has a low radiation exposure and the costs are bearable
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(Kanis 1994a). It is also important that in a longitudinal study the repeatability
of BMD measurements is good. A disadvantage is that DXA does not take into
account the size and the shape of bones and thus gives only an areal, not volu-
metric bone density (Kanis 1994a). This may bias the results especially when
BMD is measured in children. Since growth delay was an important risk factor
for reduced areal BMD in patients with SCT in childhood (study III), quantita-
tive computed tomography (QCT) might have been more informative in study-
ing these patients. Also the inability to distinguish between trabecular and corti-
cal bone is a disadvantage in DXA measurements when compared to QCT
(Kanis 1994a).
6.1.3 Markers of bone metabolism
Since different markers reflect different phases of the bone remodelling process
we used a very broad spectrum of bone turnover markers to study the mecha-
nisms of bone loss (Fohr et al 2003). Serum B-ALP, PINP and PICP were used as
the markers of bone formation. Serum OC is mainly a marker of bone forma-
tion, but to some degree, also a marker of bone resorption. Serum ICTP was
measured as a marker of MMP-related bone resorption, serum CTX and urinary
NTX as the markers of cathepsin-K-related bone resorption and serum
TRACP5b as a marker of osteoclast function. OC and the degradation products
and propeptides of bone-derived collagen are filtered in the kidneys, and thus
kidney function may affect their concentrations in serum and urine (Eyre 1996).
In all the studies serum creatinine was measured to exclude a clinically signifi-
cant kidney dysfunction and to estimate an impact of renal function on markers
of bone metabolism.
6.2 Magnitude and timing of bone loss
6.2.1 Bone mineral density
In study I the mean bone loss at the LS was 5.8 % at 6 months and 3.6 % at 12
months after SCT. At the FN bone loss was 7.0 % 6 months and 8.0 % 12 months
after SCT. In a longitudinal study of 29 recipients of allogenic SCT, patients lost
3.9 % of the lumbar spine BMD, 11.7 % of the femoral neck BMD and 3.5 of the
total body mineral content (TBMC) during approximately 30 post-transplant
months after SCT (Ebeling et al 1999). In another study bone loss was 7.2 % at
the LS. 11.9 % at the FN and 3.8 % in the TBMC one year after SCT (Schulte et
al 2000). A third study showed that 49 % of the SCT patients had osteopenia
even before transplantation and that BMD of the trabecular bone. measured by
QCT, decreased by 13 % during 6 and 16.9 % during 12 post-transplant months;
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the respective cortical bone losses were 9.8 % and 9.0 % (Massenkeil et al 2001).
In a fourth study the lumbar BMD decreased by 3.3 % and the femoral BMD by
8.9 % during the first year after BMD (Lee et al 2002a).
Collectively, our findings are in line with other studies and support the notion
that the majority of bone loss occurs during the first six months after SCT and
that the upper femur is injured more than the lumbar spine. In the latter site the
BMD even slightly recovers from 6 to 12 months after SCT.
These findings differ from those obtained after an autologous SCT. A cross-
sectional study of 64 patients, performed with a median of 4.2 years after an au-
tologous SCT, showed that the BMD of the lumbar spine did not differ from
healthy controls. Instead, 46 % of patients had osteopenia and 8 % osteoporosis
in the FN (Schirmer et al 2001). Another cross-sectional study of 29 patients
found no osteopenia five years after an autologous SCT (Kellholz et al 1997).
One longitudinal study of 10 patients showed only non-significant changes in
the FNBMD (1.1 %) and in the TBBMC (–3.7 %) or even a significant increase
(+1.5 %) at the spine one year after an autologous SCT (Ebeling et al 1999). In
another longitudinal study of 5 patients LSBMD and FNBMD decreased non-
significantly (-0.8 % and -0.5 %, respectively) during the first year after SCT
(Schulte et al 2000). Instead, in the same study the total body BMD decreased
significantly by 4.1 % (Schulte et al 2000).
Apparently the autologous SCT is, at least at the LS, bone-sparing in compari-
son to the allogeneic SCT. Instead, at the FN there is discrepancy between the
different studies. The most striking difference between these procedures, and a
reason for the better bone outcome, is the lack of need of GVHD prevention and
treatment in autologous SCT patients.
6.2.2 Osteopenia and osteoporosis
In study I 39 % of the patients had either osteopenia (34 %)or osteoporosis (5
%) at the LS before SCT, 50% (43 % osteopenia, 7 % osteoporosis) 6 months
and 37 % (34 % osteopenia, 3 % osteoporosis) 12 months after SCT. The respec-
tive numbers at the FN were 25 % (all osteopenia), 45 % (42 % osteopenia, 3%
osteoporosis), and 58 % (55 % osteopenia, 3 % osteoporosis). Buchs et al re-
ported in a cross-sectional study that 35 % of SCT patients had osteopenia in
the upper femur at the time of transplantation and 43 % osteopenia and 7 % os-
teoporosis approximately 60 months after SCT (Buchs et al 2001). Another
study reported 24% and 4% prevalences of lumbar osteopenia and osteoporosis,
respectively, before transplantation (Schulte et al 2000). Thus, taking all these
findings together, 25-40 % of SCT patients have decreased BMD even before
transplantation, and the number of patients with reduced BMD increases dur-
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ing the first six months after SCT both at the LS and the FN. Thereafter, the
bone status stabilises at the spine but still worsens at the hip.
6.2.3 Fractures
In study I the x-ray of the lumbar spine revealed new vertebral fractures in 16 %
of the patients. Our findings are in line with the results of other studies of SCT
patients, in which the incidence of new vertebral fractures has been up to 14%
during the first post-transplant year (Ebeling et al 1999, Gandhi et al 2001). Our
study population was small in number from which to draw firm conclusions but
in comparison to patients with solid organ transplantations with even a 50 %
incidence of fractures, the fracture rate seemed to be lower (Shane 1996).
6.2.4 Comparison to solid organ transplantations
The amount and timing of bone loss is quite equal after solid organ and stem
cell transplantations (Shane 1999, Cohen and Shane 2003). In spite of the simi-
larities in bone loss, patients with solid organ transplantations seem to experi-
ence more fractures than patients with haematological transplantations (Cohen
and Shane 2003). This might be due to impaired quality of bone in solid organ
transplant recipients, which cannot be measured by DXA (Maalouf and Shane
2005).
6.3 Mechanisms of bone loss after stem cell transplantation
6.3.1 Markers of bone formation
In study I all the markers of the bone formation (bone ALP, PINP and PICP) de-
creased 3 weeks to 3 months after SCT. Thereafter they returned to the baseline
at 6 months and tended to be even higher at 12 months after SCT. Also other
studies have reported similar decreases in bone ALP and PINP during the first
months after SCT (Carlson et al 1994, Ebeling et al 1999). Similar results have
been reported also in studies that have used OC as a marker of bone formation
(Gandhi et al 2000, Buchs et al 2001). Buchs et al (2001) found a positive inverse
correlation between decreases in BMD and serum OC during the first months af-
ter SCT. As a sign of the normalisation of bone formation, the studies II and III
showed PINP and OC levels in the long-term survivors of SCT similar to those
in healthy controls.
The finding that the markers of bone formation first rapidly decrease and then
increase to an even higher level than before SCT supports the theory that bone
loss during the first six post-transplant months is due to glucocorticoids, which
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inhibit bone formation (Lukert and Raiz 1990), and thereafter due to CyA,
which enhances both formation and resorption (Movsowitz et al 1988). Anoth-
er explanation for reduced bone formation soon after SCT might be damage to
the osteoprogenitor cells. Lee et al reported in an in vitro study that the differen-
tiation of bone marrow stromal cells to osteoblasts was slower in SCT recipients
than in healthy controls. Myeloablative therapy was considered a reason for the
damage to the osteoprogenitor cells (Lee et al 2002a). It might be concluded
that a decrease in bone formation is at least partly responsible for bone loss dur-
ing the first months after SCT.
6.3.2 Markers of bone resorption
In study I serum ICTP was elevated even before transplantation, increased fur-
ther during the first months after SCT and then decreased to a level, which was
still higher than before SCT. Similar findings have been obtained also in other
studies (Kang et al 2000, Lee et al 2002a). The acceleration of bone resorption af-
ter SCT has been documented also by using urinary CTX (Banfi et al 2001),
NTX (Schulte et al 2000) and pyridinium cross-links (Ebeling et al 1999) as its
markers. In one study urinary excretion of deoxypyridoline, which was elevated
before SCT, first decreased during the first weeks after SCT and then increased
during the next few months to a 20 % higher level than before SCT (Massenkeil
et al 2001).
In study II serum ICTP had decreased from the level at 12 months after SCT
but it was still higher in long-term survivors of SCT than in controls. At the
same time urinary NTX was lower in patients than in controls. In contrast, in
study III there were no differences in resorption markers either between patients
and controls or between patients with normal and reduced BMD.
In study IV, in patients not receiving pamidronate, who lost bone at all meas-
urement sites, serum ICTP was most consistently elevated; serum TRACP5b was
temporarily elevated at 1 month. Serum ICTP was elevated also in patients who
received pamidronate and lost bone at the hip; in them other resorption mark-
ers (NTX, CTX, TRACP5b) were either consistently or temporarily decreased.
6.3.3 Discrepancy between resorption markers
Even though increased bone resorption after SCT has been demonstrated by
other investigators (Ebeling et al 1999, Kang et al 2000, Schulte et al 2000, Banfi
et al 2001, Lee et al 2002a) using such resorption markers as NTX, CTX, and py-
ridinium cross-links, in our studies serum ICTP has been the most consistently
elevated resorption marker also in long-term survivors of SCT.
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This discrepancy between the bone resorption markers could be explained by
two different enzyme pathways, which degrade collagen. It is thought that
cathepsin-K mostly release CTX and NTX and MMPs ICTP (Garnero et al 1998,
Atley et al 2000, Sassi et al 2000, Garnero et al 2003). These enzymes are excreted
by osteoclasts (Fohr et al 2003). Collectively, these findings could mean that
MMP-mediated resorption of bone is important in immediate bone loss and
continues also long after SCT whereas cathepsin-K-mediated resorption is nor-
malised over time either by treatment or spontaneously.
6.3.4 Oestrogen and testosterone
Sex steroids conserve bone mass through action on both osteoblasts and osteo-
clasts (Riggs et al 2002). In estrogen deficiency, the activity of osteoclasts exceeds
that of the osteoblasts resulting in net bone loss. The delay in menarche until 16
years or older has been associated with an increased risk of vertebral fractures in
later life (Rubin et al 1999). Logically, individuals who achieve a low peak bone
mass in young adulthood are likely to develop osteoporosis later in life (Roy et
al 2003). In study III at the highest risk of reduced bone mass were females,
which were prepubertal at the time of SCT. They might not have achieved a nor-
mal peak bone mass at all due to early gonadal hormone and/or growth hor-
mone insufficiency. TBI evidently has a role in the development of hypogonad-
ism, but the independent effect of TBI on the maturing bone could not be evalu-
ated in our series since nearly all the patients were conditioned with TBI. The
fact that testosterone secretion is preserved better in males than estrogen secre-
tion in females after TBI may explain the accumulation of females in the group
of patients with reduced BMD in study III. In study I serum testosterone level
decreased but in study IV testosterone replacement was unable to prevent bone
loss. Thus the lack of sex steroids seems not to be a major mechanism of post-
SCT bone loss.
6.3.5 Osteoprotegerin
In study V no decrease in serum OPG was observed after SCT, instead OPG in-
creased significantly in both treatment groups and also in patients not receiving
any special prevention of osteoporosis. Thus post-transplant bone loss could
not be explained by decreased production of OPG. When compared to healthy
controls our patients had similar serum OPG levels before SCT and they even in-
creased after SCT. In a previous study serum OPG levels were normal in patients
with leukaemias, low in those with multiple myeloma and high in patients with
Hodgkin’s disease or non-Hodgkin’s lymphoma (Lipton et al 2002).
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Perhaps the elevated OPG levels reflect a protective mechanism of the skeleton
against increased osteoclastic activity and stimulated bone resorption. Keeping
in line with this contention we and others have shown that serum and urine
markers of bone resorption rapidly increase after SCT (Välimäki et al 1999, Ebe-
ling et al 1999, Kang et al 2000, Schulte et al 2000, Lee et al 2002a). In one study
of liver transplant recipients elevated serum OPG levels correlated positively
with elevated serum CTX concentrations (Fahrleitner et al 2002).
6.3.6 sRANKL
In study V before SCT serum sRANKL levels were similar in patients and con-
trols, remained at the control level in patients who received only calcium, vita-
min D, and sex hormone replacement therapy, and decreased in those who re-
ceived additional pamidronate. To our knowledge, serum sRANKL concentra-
tions have not been hitherto studied in haematological malignancies or in con-
junction with SCT.
Interestingly and fitting well to the role of OPG as a decoy receptor that is able
to neutralise both the cell-bound and soluble forms of RANKL, OPG and sRAN-
KL concentrations inversely correlated in the second part of study V. After all,
our findings do not support the view that the excess of sRANKL contributes to
bone loss after SCT, but serum concentrations do not necessarily reflect the situ-
ation at the tissue level.
6.3.7 Renal dysfunction
In studies I and IV the mean level of serum creatinine increased but none of the
patients developed clinically significant renal dysfunction. By the time of study
II serum creatinine had returned to the pre-transplantation level. It is unlikely
that this slight impairment in renal function affected the levels of the collagen
degradation products, which are excreted by the kidneys. On the other hand,
the major changes in the makers of bone metabolism took place earlier than the
elevation in serum creatinine.
6.3.8 Vitamin D
In study II serum 25-OH-D was significantly lower in patients than in the con-
trols. Twenty-four out of 27 patients and 11 of the 28 controls had hypovitami-
nosis D, when S-25- OH-D >_ 37,5 nmol/l was used as a cut-off criterion. This is
the level at which the serum PTH concentration has begun to rise in cross-sec-
tional studies (Thomas et al 1998). In study III six out of the 16 patients and
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eight of 23 healthy controls had low serum 25-OH-D. These findings reflect the
poor vitamin D status of the general Finnish population (Kauppinen-Mäkelin et
al 2001). In two longitudinal studies both serum 25-OH-D and 1,25-(OH)
2
-D
concentrations were low even before SCT and they further decreased concomi-
tantly with a rise in serum PTH during the first months after transplantation
(Massenkeil et al 2001) although patients in the other study received vitamin D
200 IU daily (Schulte et al 2000). After all, the impact of vitamin D status and
deranged vitamin D metabolism on SCT-associated bone loss remains open.
6.3.9 Role of immunosuppressive agents
As presented before, the changes in BMD are quite small after autologous trans-
plantation. A major difference between autologous and allogeneic SCTs is the
use of immunosuppressive regimens in conjunction with the latter. Further-
more, only a minority of patients with autologous SCT receive TBI-based condi-
tionings (Shank and Hoppe 2004). The role of the immunosuppressive medica-
tion has been well documented in solid organ transplantation -associated bone
loss (Epstein 1996). In study II the long-term users of GVHD prophylaxis [> 1
year, total MP dose 9.7 (5.3) g and CyA dose 81.5 (48.0) g] total bone loss from
the pre-transplant level at the femoral sites was significantly higher than short-
term users’ [ total MP dose 3.6 (2.6)g and CyA dose 71.3 (17.3)g]. Ebeling et al
showed that bone loss after SCT was higher the higher  the cumulative dose of
glucocorticoids and the longer  the duration of exposure to CyA (Ebeling et al
1999). In another study bone loss in patients who did not receive glucocorti-
coids was significantly lower than in those who were treated with them (Schulte
et al 2000).
In the long-term the cortical bone of the upper femur appears to be more vul-
nerable to SCT than the trabecular bone of the vertebrae. Trabecular bone loss
occurs during the first months after SCT, decreases thereafter, and the bone sta-
tus of the lumbar spine even recovers spontaneously. In the upper femur BMD
continues to decrease. During the use of glucocorticoids, the BMD of the trabec-
ular bone decreases faster than that of the cortical bone (Lukert and Raiz 1990).
Instead CyA affects both trabecular and cortical bones (Epstein 1996). Conse-
quently, rapid bone loss during the first six months after SCT may be mostly due
to glucocorticoids and afterwards CyA is the main drug affecting bone. The re-
modelling cycles of the trabecular bone are more rapid than those of the cortical
bone (Aurbach et al 1992b), also facilitating a quicker recovery of the bone.
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6.4 Recovery of bone after stem cell transplantation in adults
Study II demonstrated that BMD increased at all measurement sites from one
year after SCT to the follow-up visit approximately 6 years after SCT. The recov-
ery was statistically significant at the LS.
A longitudinal study of 35 patients for two post-transplant years showed a
slight increase in the spinal BMD from one to two years after SCT, and a further
loss in the femoral neck BMD (Schulte et al 2000). A cross-sectional study per-
formed approximately 3 years (range 1-10 years) after SCT showed that BMD in
patients was significantly lower than in controls and 17 % of them had osteope-
nia and 12 % osteoporosis at the LS and 37 % osteopenia and 15 % osteoporosis
at the FN. When phalangeal osteosonogrammetry was used 60 % (25 out of 41)
had osteopenia and 7 % (3 out of 41) osteoporosis. The more time had elapsed
from transplantation the higher the BMD values, especially in the spine (Tauch-
manova et al 2002). It has been demonstrated also in other studies that the BMD
of the femoral neck is lowered 60 (5,6) months and 2 and 5 years after SCT
(Buchs et al 2001, Gandhi et al 2003). The latest study demonstrated that the
lumbar spine BMD reached its nadir at 6 months and the femoral neck BMD at
24 months (Schulte and Beelen 2004).
Taken together all these findings support the view that the lumbar spine BMD
recovers but the femoral neck BMD remains lowered for years after SCT. A high
rate of osteopenia in the phalanges, which as the upper femur mainly consists of
cortical bone, supports the contention that cortical rather than trabecular bone
is injured in the SCT.
6.5 Effect on peak bone mass of stem cell transplantation performed in
childhood
In study III, six out of 16 patients (38 %) had a significantly reduced areal BMD
(Z-score < -1) at, at least, one measurement site, the median Z-scores being –
0.25, -0.4 and –0.2 for the LS, the FN and the total body, respectively. The risk of
belonging to the group of reduced bone mass associated with female gender, pre-
pubertal status at the time of SCT, pubertal growth delay, hypogonadism, and
low BMI. Also in another study the total body BMD (median Z-score –0,5) 2
(range 1-10) years after SCT was lower (p=0,03) in paediatric patients who had
received allogeneic SCT during childhood compared to those who had received
SCT as adults (median Z-score 0,0). That study did not find a correlation be-
tween reduced bone mass and hypogonadism, intake of glucocorticoids or
GVHD (Bhatia et al 1998).
In study III no correlations between the doses of immunosuppressive drugs
and BMD were found although they were shown in study II and in adult patients
65
by others (Ebeling et al 1999). Perhaps the harmful effects of CyA and glucocor-
ticoids in the growing bone at least in part disappear when enough time has
elapsed since they stop being taken. Lack of GH and sex steroids may lead to
more stable bone loss
Growth hormone (GH), partly via action of IGF-I, stimulates both osteob-
lasts and osteoclasts with the net effect being bone accumulation (Olney 2003).
GH deficiency impairs the accumulation of bone mass in children (Saggese et al
1992) but also disturbs the maintenance of BMD in adults (Holmes et al 1994).
In children with primary pituitary deficiency GH replacement does not totally
prevent bone loss (Kaufman et al 1992). GH deficient children achieve lower
peak bone mass than healthy controls (Monson et al 2002). It can be thought
that a lack of GH is a major threat to bone health of children who undergo a
stem cell transplantation. Whether GH therapy should be continued until peak
bone mass is achieved, should be examined in further studies.
In study III patients with reduced bone mass had a lower body mass index
(BMI) than those with normal BMD. Low BMI predisposes to bone loss (Grisso
et al 1997, Bass et al 1999) and increases the risk of fractures in both genders
(Roy et al 2003). In our study the patients with low BMI had also a lack of GH,
which by decreasing muscle mass affects BMI (Weber 2003).
 Height is an important positive determinant of peak bone mass in young
adults (Välimäki et al 2004). In the present study, this was true only for those
with normal BMD. A new finding was the negative relationship between height
in SDs and areal bone mineral density in SCT patients with reduced BMD, espe-
cially in the lumbar spine. This implies that the vertebrae were denser the more
the patient’s growth was retarded. Dense vertebrae might result from fractures
in the lumbar spine. However, none of our patients had been diagnosed with
vertebral fractures during the post-transplant follow-up. It could be hypothe-
sised that growth delay might even extend the period of bone mineralisation. Fi-
nally, growth retardation in SCT recipients may involve the appendicular more
than the axial skeleton.
Taken together, low peak mass in young adults with SCT in  childhood associ-
ates with female gender, prepubertal status, growth retardation, hypogonadism
and low BMI. Unfortunately, due to the small number of subjects we were not
capable of performing multivariate analyses to reveal independent determinants
of low peak bone mass.
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6.6 Prevention of stem cell transplantation associated bone loss
6.6.1 Vitamin D and calcium
In study I calcium either alone or with calcitonin had no significant effect on
bone loss. In  study IV all patients received calcium and vitamin D but they
could not prevent bone loss, the magnitude of which was the same as in  study I.
Similar results have been obtained in cardiac transplant recipients (Välimäki et
al 1999), who in another study benefited from a high dose (32000 IU per week)
of calcidiol (25-OH-D) even more than from a low dose of nasal calcitonin or
cyclical etidronate with respect to their BMD (Garcia-Delgado et al 1997). Al-
though the evidence to support the role of calcium and vitamin D in the preven-
tion of transplantation-associated bone loss is scarce, their use is generally rec-
ommended to all transplant recipients (Cohen and Shane 2003).
6.6.2 Calcitonin
Calcitonin together with calcium had no significant effect on bone loss. The
same kind of results have been obtained in cardiac transplant recipients (Garcia-
Delgado et al 1997, Välimäki et al 1999). Although calcitonin reduces glucocorti-
coids-induced bone loss (Rodino and Shane 1998) it does not seem to be effective
enough in organ transplantation recipients.
6.6.3 Sex steroids
Oestrogen replacement decreases the risk of fractures in postmenopausal women
(Rubin et al 1999, Roy et al 2003). In our studies females who developed amenor-
rhoea as a sign of hypogonadism, received oestrogen replacement therapy. In
study I the replacement therapy was started quite late, on average 6 months af-
ter SCT, which might have been too late to prevent bone loss at least at the LS.
However, in study IV the females who started oestrogen replacement without
pamidronate immediately after SCT lost bone at the LS and the FN no less than
the women in study I over the first 6 post-transplant months. In line with our
findings, Gandhi et al showed that females, who started oestrogen replacement
during the first year after SCT, had a bone loss equal to that of other SCT pa-
tients (Gandhi et al 2003). In one study oestrogen improved BMD in osteopenic
females when started 13 months after SCT (Castelo-Branco et al 1996). Al-
though oestrogen replacement therapy is effective in postmenopausal oste-
oporosis and possibly in SCT patients when started later on, it does not seem to
prevent immediate bone loss after SCT. If oestrogen therapy is not contraindi-
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cated, it might be useful for female recipients of SCT to treat hypogonadal
symptoms but not to prevent bone loss.
Study I showed a remarkable reduction in the serum testosterone level of male
patients with the nadir at six weeks after SCT. In line with the results of another
Finnish study (Kauppila et al 1998), four out of 13 males in study II were hypog-
onadal and all men had lower serum testosterone levels than before transplanta-
tion. At the time of the re-examination there was no significant difference in
BMD between hypo- and eugonadal men but the hypogonadal men were all
short-term users of immunosuppressive drugs. In study IV, in which for all
males testosterone replacement therapy was started early after SCT, those who
did not receive pamidronate lost bone both at the LS and the FN. Although
treatment of male hypogonadism of various causes has improved BMD (Snyder
et al 2000), our findings do not support the role of testosterone replacement
therapy in the prevention of SCT-associated bone loss. It is, however, recom-
mended for truly hypogonadal men (Rodino and Shane 1998).
6.6.4 Bisphosphonates
In study IV pamidronate prevented bone loss at the LS but only decreased it at
the femoral sites in comparison with the combination of calcium, vitamin D,
and sex steroid replacement only.
There are no other randomised, prospective studies where the efficacy of bi-
sphosphonate therapy has been tested in SCT recipients. In a non-randomised
study (n=33), where 79 % of patients either used oestrogen raplacement therapy
or three-monthly infusions of 30 mg pamidronate, BMD of the LS remained af-
ter SCT but decreased at the FN by –4.2 % at 6 and by –5.6 % at 12 months after
SCT (Buchs et al 2001). Instead in randomised studies where treatment was
started not earlier than 17 to 24 months after SCT, risedronate or zoledronic
acid either prevented further bone loss or even increased BMD at the femoral
neck (Tauchmanova et al 2003, Tauchmanova et al 2004).
Our results are comparable to those obtained in a recent study of cardiac
transplant recipients where alendronate prevented bone loss at the LS but only
decreased it at the FN during the first post-transplant year (Shane et al 2004). A
prospective, randomised study in kidney transplantation patients showed that
intravenous zoledronic acid prevented femoral bone loss and even increased
BMD at the LS during the first six months after the transplantation (Haas et al
2003). In another prospective, randomised study of kidney transplant recipients
intravenous ibandronate prevented lumbar bone loss and even improved femo-
ral BMD while patients without treatment lost bone at both sites (Grotz et al
2001). A single dose of pamidronate followed by cyclic etidronate reduced bone
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loss both at the LS and the FN compared to historical controls after cardiac
transplantation (Shane et al 1998). Liver transplantation patients with reduced
bone mass before transplantation had no new vertebral fracture when treated
with intravenous pamidronate before and nine months after the procedure. At
the same time 38 % of untreated patients had new fractures (Reeves et al 1998).
Lung transplantation patients treated with cyclic etidronate had less bone loss
both at the LS and the FN than controls (Henderson et al 2001). Bisphospho-
nates have also either prevented further bone loss or increased BMD when they
have been started from six months to several years after cardiac, kidney or liver
transplantation (Valero et al 1995, Giannini et al 2001, Dodidue et al 2003).
High serum levels of ICTP might offer one mechanistic explanation for the rel-
ative inefficacy of pamidronate in the prevention of bone loss at the hip. ICTP is
thought to reflect matrix metalloproteinase (MMP)-mediated bone resorption
and CTX and NTX cathepsin-K-mediated resorption (Atley et al 2000, Sassi et al
2000, Garnero et al 2003). Bisphosphonates inhibit cathepsin-K mediated re-
sorption and decrease NTX and CTX (Garnero et al 1994,Christcau et al 2000,
Garnero et al 2003), but not serum ICTP. Consequently, a possibility remains
that MMP-mediated bone resorption significantly contributes to immediate
bone loss in SCT patients and this is not prevented with bisphosphonates.
TRACP5b is a novel and specific marker of the osteoclast function (Halleen et al
2001, Janckila et al 2001) and should reflect both MMP- and cathepsin-K-medi-
ated bone resorptions by osteoclasts. In the pamidronate-treated patients
TRACP 5b was lowered below the pre-transplantation level but ICTP remained
elevated 6 to 12 months after the procedure. Consequently, a question arises
where the possibly increased MMP activity resides - in osteoclasts or possibly in
osteoblasts (Chanbers et al 1985, Blavier and Delaisse1995).
The mechanisms by which bisphosphonates inhibit osteoclasts are not totally
clear. Data concerning the effect of bisphosphonates on the OPG/RANKL system
is controversial. In a rat osteosarcoma cell line, pamidronate and clodronate
down-regulated the expression of mRNA of RANKL (Pan et al 2004). In one
study different concentrations of alendronate or pamidronate did not change
the messengerRNA expression of RANKL or OPG in bone cells of mice (Kim et al
2002). In another study zoledronic acid and pamidronate stimulated OPG pro-
duction in human osteoblast cell culture (Viereck et al 2002). In the only human
study of patients with Paget’s disease elevated serum OPG decreased after the
start of tiludronate (Alvarez et al 2003). In our study the V serum OPG concen-
tration increased similarly in patients receiving and not receiving pamidronate
but serum sRANKL decreased in patients treated with pamidronate. Thus, at
least part of the bone-sparing effects of bisphosphonate might be mediated
through the inhibition of RANKL production.
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7 CONCLUSIONS
1) BMD both at the lumbar spine and at the upper femur reduced significantly
by 5.8 % and 7.0 % during the first six months after allogeneic stem cell trans-
plantation. BMD of the lumbar spine slightly recovered during the next six
months, whereas BMD of the upper femur further decreased at least up to one
year after SCT.
2) The changes in bone turnover markers indicated that the reduction in BMD
after allogeneic SCT was a net effect of decreased bone formation and increased
bone resorption. The markers of bone formation decreased during the first 3
months after SCT but returned to the pre transplantation level by six months af-
ter SCT. The marker of bone resorption serum ICTP increased rapidly and re-
mained elevated even several years after SCT. Increased serum ICTP levels sup-
port the contention that metalloproteinase-mediated bone resorption is an im-
portant mechanism in SCT-associated bone loss. Deficiency of OPG or excess of
sRANKL did not seem to contribute to bone loss after SCT.
3) In adult SCT-recipients BMD of the lumbar spine spontaneously returned
near to the pre- transplantation level during the follow-up of a mean duration
of six years. Also the femoral BMD slightly recovered over the years after SCT
but remained lower than before transplantation.
4) On average one third of the patients, who had received a SCT during child-
hood, had a reduced bone mass in adolescence and young adulthood. Female
gender, hypogonadism, prepubertal status at the time of SCT, growth retarda-
tion and low BMI were risk factors of reduced peak bone mass.
5) Bone loss after SCT could not be prevented by calcium with or without calci-
tonin or sex hormone replacement therapy. Instead, intravenous pamidronate
prevented bone loss in the lumbar spine and decreased but did not totally abol-
ish it in the upper femur. The relative inefficacy of pamidronate in the preven-
tion of bone loss at the hip might be related to MMP-mediated bone resorption,
which is not inhibited by bisphosphonates.
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Study N Type of 
study 
LBMD  FNBMB  Prevalence of 
osteopenia/ -
porosis 
S-OPG 
 
 S-OC  S-ICTP U-NTX 
Baek et al 
2004 
36 Prospective -5.2 % in 1 
year 
-11.6% in 1 
year 
 +23 % in 3 
months 
   
Bhatia et al 
1998 
23 Cross-
secional 
  Total body Z-
score –0.5 2 
years after SCT 
    
Buchs et al 
2001 
23 Prospective -4.2 %in 1 
year 
-5.6 % in 1 
year 
     
Castañeda 
et al 1997 
27 Cross-
sectional 
  33 %/18% 13 
months after 
SCT 
    
Ebeling  
et al 1999 
29 Prospective -3.9 % in 1 
year 
-11.7 % in 
1 year 
     
Gandhi et 
al 2003 
44* Prospective -2.4 % in 6, 
0.001 % in 
24 months 
-5.2 % in 6, 
–4.2 % in 
24 months 
  + 12 % in 3 
months 
  
Kang et al 
2000 
31 Prospective -2.2 % in 1 
year 
-6.2 % in 1 
year 
  -150 % in 3 
weeks 
+ 57 % in 4 
weeks 
 
Kelly et al 
1990 
23 Cross-
sectional 
  all had lowered 
BMD 1 year 
after SCT 
    
Lee et al 
2002 
67 Prospective -3.3 % in 1 
year 
-8.9 % in 1 
year 
  -65 % in 3 
weeks 
+73 % in 4 
weeks 
 
Lee et al 
2004 
46 Prospective -4.8 % in 
1year 
-12.3 % in 
1 year 
  -64 % in 3 
weeks 
+85 % in 4 
weeks 
 
Massenkeil 
et al 2001 
67 Prospective   T score –0.87 
before, –1.71 1 
year after SCT 
    
Schulte et 
al 2001 
81 Prospective -7.2 % in 1 
year 
-11.9 % in 
1year 
24 %/4 % % 
before, 44 %/ 5 
% 1 year after, 
40 %/ 9 % 2 
years after SCT 
   + 30 % 
in 2 
weeks  
Schulte et 
al 2001 
280 Prospective -5.9 % in 1 
year, -2.9 % 
in 4 years 
-8.5 % in 1 
year, -11 % 
in 4 years 
     
*
Table 1 Summary of studies of bone metabolism after allogeneic stem cell transplantation
*= Includes 30 patients with autologous transplantation
Abbreviation: FBMD= bone mineral density of femoral neck, ICTP= type I collagen carboxytermi-
nal telopeptide, LBMD= bone mineral density of lumbar spine, NTX= type I collagen aminotermi-
nal telopeptide, OC= osteocalcin; OPG= osteoprotegerin, SCT= stem cell transplantation
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Table 2 Characteristics of the patients
 
 
Study I 
Study II  
Study III 
Study IV
 
Study V
 
 
N
o 
treatm
ent 
C
alcium
 
C
alcium
+
calcitonin 
Patients* 
C
ontrols 
Patients 
C
ontrols 
Pam
i+
 
Pam
i- 
Pam
i+
# 
Pam
i-
# 
O
ther 
part 
C
ontrols 
N
um
ber 
22 
12 
10 
27 
28 
16 
24 
35 
37 
14 
16 
28 
21 
A
ge (years) 
40 (10) 
40 (8) 
41 (12) 
44 (9) 
35 (12) 
21 (5) 
23 (4) 
41 (13) 
44 
(10) 
38 (13) 
43 (10) 
40 (10) 
43 (12) 
F/M
 
10/12 
9/3 
4/6 
14/13 
14/14 
(10/6) 
12/12 
17/18 
19/18 
8/6 
8/8 
14/14 
11/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prim
ary disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
   A
M
L 
10 
5 
2 
12 
 
5 
 
10 
10 
5 
4 
14 
 
   A
LL 
4 
1 
1 
2 
 
5 
 
6 
4 
3 
1 
5 
 
   C
M
L 
7 
2 
6 
10 
 
2 
 
13 
14 
4 
6 
6 
 
   C
LL 
 
 
 
 
 
 
 
2 
2 
1 
2 
1 
 
   M
D
S 
1 
1 
 
2 
 
1 
 
2 
1 
1 
0 
 
 
   lym
phom
a 
 
1 
 
1 
 
 
 
1 
3 
0 
1 
 
 
   M
F 
 
 
 
 
 
 
 
1 
3 
0 
2 
 
 
   A
A
 
 
 
 
 
 
3 
 
 
 
 
 
1 
 
…
H
ybrid 
leukaem
ia 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
um
ulative 
dose of M
P (g) 
 
 
 
 
 
 
 
 
 
 
 
 
 
   at 6 m
onths 
3.6 (0,5) 
5.5 (0,7) 
5.1 (0.8) 
 
 
 
 
3.1 (2.2) 
2.7 
(2.2) 
3.7 (2.2) 
3.0 
(2.9) 
 
 
   at 12 m
onths 
4.4 (0.6) 
5.8 (0.8) 
5.9 (0.8) 
4.4 (2.6) 
 
 
 
4.3 (2.7) 
3.3 
(2.6) 
4.5 (3.1) 
3.8 
(3.4) 
 
 
   total 
 
 
 
6.3 (5) 
 
4,0 
 
 
 
 
 
2.1 (1.2) 
 
C
um
ulative 
dose of C
yA
 (g) 
 
 
 
 
 
 
 
 
 
  
  
 
 
   at 6 m
onths 
38.2 (4.0) 
40.4 (5.3) 
46.2 (5.8) 
 
 
 
 
43.8 
(17.0) 
43.3 
(14.4) 
47.9 
(18.1) 
46.3 
(14) 
 
 
   at 12 m
onths 
62.1 (4.3) 
68.1 (5.7) 
77.2 (7.0) 
67.1 
(20.8) 
 
 
 
67.6.
(31.6) 
66,0 
(27.6) 
78.2 (34) 
79.6 
(25.7) 
 
 
   total 
 
 
 
75.8 
(34.1) 
 
25,6 
 
 
 
 
 
28 (9.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q
uestions, 
w
hich study 
answ
ered 
I, II, V
 
III 
IV
 
V
 
II 
 
 
 
 
 
 
 
 
· *= the same patients as in study I, # = the same patients as in study IV
· Abbreviations: pami= pamidronate, AML= acute myeloblastic leukaemia, ALL= acute
lymphoblastic leukaemia, CML= chronic myeloid leukaemia, CLL= chronic lymphocytic
leukaemia, MDS= myelodysplastic syndrome; MF= myelofibrosis, AA= amyloidosis, MP=
methylprednisolone, CyA= cyclosporine A
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Table 3 The number of patients having osteopenia or osteoporosis at the lumbar spine
 Study I  Study II Study IV 
     Pami + Pami - 
           
Time  before 6 mt 12 mt Follow-up before 6 mt 12 mt before 6 mt 12 mt 
Osteopenia 
(also in study II) 
15 (10) 17 (12) 16 (12) 7 10 8 7 11 12 7 
Osteoporosis 
(also in study II) 
2 (1) 3 (1) 1 (1) 0 1 1 1 4 5 4 
Total (also in 
study II) 
17 (11) 20 (13) 17 (13) 7  11 9 8 15 17 11 
% of whole 
group (also in 
study II) 
39 (41) 50 (57) 47 (50) 26 31 26 24 41 46 34 
           
           
Table 4 The number of patients having osteopenia or osteoporosis at the femoral neck
 Study I  Study II Study IV 
     Pami + Pami - 
           
Time  before 6 mt 12 mt Follow-up before 6 mt 12 mt before 6 mt 12 mt 
Osteopenia 
(also in study II) 
11 (7) 17 (9) 20 (11) 10 9 10 10 14 18 15 
Osteoporosis 
(also in study II) 
0 (0) 1 (1) 1 (1) 1 3 3 3 2 3 1 
Total (also in 
study II) 
11 (7) 18 (10) 21 (12) 11  12 13 13 16 21 16 
% of whole group 
(also in study II) 
25 (27) 45 (43) 58 (48) 41 34 37 40 43 56 48 
           
           
Table 5 Bone mineral density in young adults medially 7.1 (range 1.5-20.5) years after stem cell
transplantation. Bone mineral density is presented as standardized for age and gender  (Z-score).
Percentages indicate the proportion of the whole study group (n=16).
 Z-score (SD) Z-score less than equal 
to –1  
n (%) 
L1-L4 
   All 
   Men 
   Women 
 
-0.2 (1.0) 
0.6 (0.7) 
-0.5 (1.1) 
 
3 (19) 
0 (0) 
3 (30) 
Femoral neck* 
   All 
   Men 
   Women 
 
-0.4 (1.3) 
-0.3 (0.4) 
-0.7 (1.8) 
 
2 (13) 
0 (0) 
2 (33) 
Total hip* 
  All 
  Men 
  Women 
 
 
-0.1(1.2) 
0.2 (0.4) 
-0.9 (1.6) 
 
1 (6) 
0 (0) 
1 (17) 
Total body 
   All 
   Men 
   Women 
 
-0.2 (1.0) 
0.3 (0.5) 
-0.4 (1.1) 
 
4 (25) 
0 (0) 
4 (40) 
 
* not available  in five subjects less than 20 years
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                                                                                               Osteoblast 
 
                                                                                              
 
 
 
 
                                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Schematic view of bone remodelling
Figure 2 Local regulation of bone remodelling. IL-1, 6, 11= interleukins 1,6,11, TNF = tumour
necrosis factor, GM-CSF=granulocyte-macrophage colony stimulating factorM-CSF= macrophage-
colony stimulating factor, RANKL = receptor activator of NF-êB ligand, RANK = receptor activator
of NF-êB, OPG = osteoprotegerin, TGFâ= transforming growth factor â
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Figure 6 
Figure  
Figure 3 Bone loss in the combined population of the study I. Changes in BMD (mean and SE) as
per cent from baseline between 0 and 6 months, 6 and 12 months and 0 and 12 months after SCT.
* p<0,0001 for changes from baseline.
Figure 4 Markers of bone turnover (mean and SE) in the combined population of study I. (a) se-
rum bone-specific alkaline phosphatase; (b) serum procollagen I carboxyterminal propeptide; (c) se-
rum procollagen I aminoterminal propeptide; (d) serum collagen I carboxyterminal telopeptide. *
92
i ( ) ( ) i (S ) i SC i
A. OPG
Time (months)
0 1 3 6 12
pm
ol
/l
0
1
2
3
4
5
6
Pamidronate
Control
B. RANKL
Time (months)
0 1 3 6 12
pm
ol
/l
0.0
0.1
0.2
0.3
0.4
0.5
0.6
RM ANOVA P = 0.050
*
* **
***
**
Figure 5 Serum osteoprotegerin (A) and sRANKL (B) concentrations [mean(SE)] in SCT patients
receiving and not receiving pamidronate. RM ANOVA for a difference between the groups over
time. * P<0.05, **P<0.01, ***P<0.001 for changes from baseline
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RM ANOVA p = 0.0084
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Figure 6 Per cent changes in bone mineral density [mean (SE)] in the study groups. A. Lumbar
spine. B. Femoral neck. C. Trochanter. D. Total hip. P values in the figures denote significancies be-
tween the groups over time (RM ANOVA). * P<0.05, ** P<0.01 for differences between the groups
at different time points. †P<0.05, †† P<0.01, ††† P<0.001 for within-group changes from base-
line.
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 Figure 7 Per cent changes in bone turnover markers (median with interquartile ranges) in the study
groups. A. PINP= serum type I procollagen aminoterminal propeptide; B. NTX= urinary type I col-
lagen aminoterminal telopeptide related to creatinine; C. CTX= serum type I collagen carboxyter-
minal telopeptide b; D. ICTP= serum type I collagen carboxyterminal telopeptide, E. TRACP5b=
serum tartrate resistant acid phosphatase 5b. * P<0.05, ** P<0.01, *** P<0.001 for differences be-
tween the groups at different time points. † P<0.05, †† P<0.01, ††† P<0.001 for within-group
changes from baseline.
